
==== Front
Diabetologia
Diabetologia
Diabetologia
0012-186X
1432-0428
Springer Berlin Heidelberg Berlin/Heidelberg

38910151
6205
10.1007/s00125-024-06205-5
Consensus Report
Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes
http://orcid.org/0000-0002-6616-5612
Phillip Moshe 12
http://orcid.org/0000-0001-6720-2684
Achenbach Peter 34
http://orcid.org/0000-0002-0508-4309
Addala Ananta 56
http://orcid.org/0000-0001-8219-6059
Albanese-O’Neill Anastasia aaoneill@breakthrought1d.org

7
http://orcid.org/0000-0002-0273-4732
Battelino Tadej 89
http://orcid.org/0000-0001-5638-4048
Bell Kirstine J. 10
http://orcid.org/0000-0002-4645-6324
Besser Rachel E. J. 1112
http://orcid.org/0000-0002-8704-4713
Bonifacio Ezio 1314
http://orcid.org/0000-0002-8345-3288
Colhoun Helen M. 1516
http://orcid.org/0000-0003-4448-8629
Couper Jennifer J. 171819
http://orcid.org/0000-0001-6004-576X
Craig Maria E. 1020
http://orcid.org/0000-0003-0773-6961
Danne Thomas 21
http://orcid.org/0000-0003-4310-6799
de Beaufort Carine 222324
http://orcid.org/0000-0001-9201-2145
Dovc Klemen 89
http://orcid.org/0000-0002-3006-4633
Driscoll Kimberly A. 252627
Dutta Sanjoy 28
http://orcid.org/0000-0002-8473-249X
Ebekozien Osagie 29
http://orcid.org/0000-0003-3306-1742
Larsson Helena Elding 3031
http://orcid.org/0009-0005-9922-7305
Feiten Daniel J. 32
Frohnert Brigitte I. 25
http://orcid.org/0000-0003-3541-1486
Gabbay Robert A. 33
http://orcid.org/0000-0002-5844-2309
Gallagher Mary P. 34
http://orcid.org/0000-0003-4451-9800
Greenbaum Carla J. 35
http://orcid.org/0000-0003-2374-0733
Griffin Kurt J. 3637
Hagopian William 38
http://orcid.org/0000-0002-2803-1824
Haller Michael J. 2739
http://orcid.org/0000-0002-0075-828X
Hendrieckx Christel 404142
http://orcid.org/0000-0002-0795-1832
Hendriks Emile 43
http://orcid.org/0000-0001-8911-6744
Holt Richard I. G. 4445
Hughes Lucille 46
http://orcid.org/0000-0003-0102-0030
Ismail Heba M. 47
http://orcid.org/0000-0002-5144-7836
Jacobsen Laura M. 39
http://orcid.org/0000-0001-5721-7524
Johnson Suzanne B. 48
http://orcid.org/0000-0003-2803-6788
Kolb Leslie E. 49
http://orcid.org/0000-0001-9563-3537
Kordonouri Olga 21
http://orcid.org/0000-0002-3636-2025
Lange Karin 50
http://orcid.org/0000-0003-2457-4888
Lash Robert W. 51
http://orcid.org/0000-0003-1735-0499
Lernmark Åke 30
http://orcid.org/0000-0002-0255-4555
Libman Ingrid 52
http://orcid.org/0000-0001-6394-7689
Lundgren Markus 3053
http://orcid.org/0000-0002-4602-7909
Maahs David M. 5
http://orcid.org/0000-0002-4415-316X
Marcovecchio M. Loredana 54
http://orcid.org/0000-0002-4055-5233
Mathieu Chantal 55
Miller Kellee M. 29
http://orcid.org/0000-0002-7774-7220
O’Donnell Holly K. 25
http://orcid.org/0000-0001-9485-2738
Oron Tal 12
http://orcid.org/0000-0001-9781-4809
Patil Shivajirao P. 56
http://orcid.org/0000-0002-2042-1350
Pop-Busui Rodica 57
http://orcid.org/0000-0003-3829-9207
Rewers Marian J. 25
http://orcid.org/0000-0003-3872-7793
Rich Stephen S. 58
http://orcid.org/0000-0002-1044-5762
Schatz Desmond A. 59
http://orcid.org/0000-0003-4604-0879
Schulman-Rosenbaum Rifka 60
http://orcid.org/0000-0003-0560-5773
Simmons Kimber M. 25
http://orcid.org/0000-0002-4393-954X
Sims Emily K. 61
http://orcid.org/0000-0003-1136-8110
Skyler Jay S. 62
http://orcid.org/0000-0002-3722-7490
Smith Laura B. 63
http://orcid.org/0000-0003-1480-4272
Speake Cate 35
http://orcid.org/0000-0002-5931-9484
Steck Andrea K. 25
http://orcid.org/0000-0003-0460-6870
Thomas Nicholas P. B. 64
http://orcid.org/0000-0002-6415-8005
Tonyushkina Ksenia N. 65
http://orcid.org/0000-0002-6557-270X
Veijola Riitta 66
http://orcid.org/0000-0002-5197-3529
Wentworth John M. 6768
http://orcid.org/0000-0003-0629-5316
Wherrett Diane K. 69
Wood Jamie R. 70
http://orcid.org/0000-0002-6290-5548
Ziegler Anette-Gabriele 34
http://orcid.org/0000-0002-8033-6078
DiMeglio Linda A. 47
1 https://ror.org/01z3j3n30 grid.414231.1 0000 0004 0575 3167 Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
2 https://ror.org/04mhzgx49 grid.12136.37 0000 0004 1937 0546 Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
3 grid.4567.0 0000 0004 0483 2525 Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany
4 grid.15474.33 0000 0004 0477 2438 Forschergruppe Diabetes, Technical University Munich, Klinikum Rechts Der Isar, Munich, Germany
5 grid.168010.e 0000000419368956 Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA USA
6 grid.168010.e 0000000419368956 Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA USA
7 https://ror.org/00vqxjy61 grid.429307.b 0000 0004 0575 6413 Breakthrough T1D, Gainesville, FL USA
8 https://ror.org/05njb9z20 grid.8954.0 0000 0001 0721 6013 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
9 https://ror.org/01nr6fy72 grid.29524.38 0000 0004 0571 7705 Department of Endocrinology, Diabetes and Metabolism, University Medical Centre Ljubljana, Ljubljana, Slovenia
10 https://ror.org/0384j8v12 grid.1013.3 0000 0004 1936 834X Charles Perkins Centre and Faculty of Medicine and Health, University of Sydney, Sydney, NSW Australia
11 grid.4991.5 0000 0004 1936 8948 JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre Human Genetics, Nuffield Department of Medicine Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
12 https://ror.org/052gg0110 grid.4991.5 0000 0004 1936 8948 Department of Paediatrics, University of Oxford, Oxford, UK
13 grid.4488.0 0000 0001 2111 7257 Center for Regenerative Therapies Dresden, Faculty of Medicine, Technical University of Dresden, Dresden, Germany
14 https://ror.org/05ke5hb07 grid.507329.a Paul Langerhans Institute Dresden, Helmholtz Centre Munich at the University Clinic Carl Gustav Carus of TU Dresden and Faculty of Medicine, Dresden, Germany
15 https://ror.org/01nrxwf90 grid.4305.2 0000 0004 1936 7988 The Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
16 https://ror.org/05x1ves75 grid.492851.3 0000 0004 0489 1867 Department of Public Health, NHS Fife, Kirkcaldy, UK
17 https://ror.org/00892tw58 grid.1010.0 0000 0004 1936 7304 Robinson Research Institute, The University of Adelaide, Adelaide, SA Australia
18 https://ror.org/00892tw58 grid.1010.0 0000 0004 1936 7304 Adelaide Medical School, The University of Adelaide, Adelaide, SA Australia
19 https://ror.org/03kwrfk72 grid.1694.a Division of Paediatrics, Women’s and Children’s Hospital, Adelaide, SA Australia
20 grid.1005.4 0000 0004 4902 0432 Discipline of Paediatrics & Child Health, School of Clinical Medicine, UNSW Medicine & Health, Sydney, NSW Australia
21 Breakthrough T1D, Lisbon, Portugal
22 International Society for Pediatric and Adolescent Diabetes (ISPAD), Berlin, Germany
23 Diabetes & Endocrine Care Clinique Pédiatrique (DECCP), Clinique Pédiatrique/Centre Hospitalier (CH) de Luxembourg, Luxembourg City, Luxembourg
24 https://ror.org/036x5ad56 grid.16008.3f 0000 0001 2295 9843 Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-Belval, Luxembourg
25 https://ror.org/03wmf1y16 grid.430503.1 0000 0001 0703 675X Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO USA
26 https://ror.org/02y3ad647 grid.15276.37 0000 0004 1936 8091 Department of Clinical and Health Psychology, University of Florida, Gainesville, FL USA
27 https://ror.org/02y3ad647 grid.15276.37 0000 0004 1936 8091 Department of Pediatrics, University of Florida Diabetes Institute, Gainesville, FL USA
28 https://ror.org/00vqxjy61 grid.429307.b 0000 0004 0575 6413 Breakthrough T1D, New York, NY USA
29 https://ror.org/016jvas21 grid.461811.b T1D Exchange, Boston, MA USA
30 https://ror.org/012a77v79 grid.4514.4 0000 0001 0930 2361 Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden
31 https://ror.org/02z31g829 grid.411843.b 0000 0004 0623 9987 Department of Pediatrics, Skåne University Hospital, Malmö and Lund, Sweden
32 Children’s Diabetes Foundation, Aurora, CO USA
33 https://ror.org/04f6cgz95 grid.427608.f 0000 0001 1033 6008 American Diabetes Association, Arlington, VA USA
34 https://ror.org/005dvqh91 grid.240324.3 0000 0001 2109 4251 NYU Langone Medical Center, New York, NY USA
35 https://ror.org/04j9rp686 0000 0004 0444 3749 Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA USA
36 https://ror.org/00sfn8y78 grid.430154.7 0000 0004 5914 2142 Sanford Research, Sioux Falls, SD USA
37 https://ror.org/0043h8f16 grid.267169.d 0000 0001 2293 1795 Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD USA
38 grid.34477.33 0000000122986657 Pacific Northwest Diabetes Research Institute, University of Washington, Seattle, WA USA
39 https://ror.org/02y3ad647 grid.15276.37 0000 0004 1936 8091 Division of Endocrinology, University of Florida College of Medicine, Gainesville, FL USA
40 https://ror.org/02czsnj07 grid.1021.2 0000 0001 0526 7079 School of Psychology, Deakin University, Geelong, VIC Australia
41 The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Carlton, VIC Australia
42 https://ror.org/02czsnj07 grid.1021.2 0000 0001 0526 7079 Institute for Health Transformation, Deakin University, Geelong, VIC Australia
43 grid.5335.0 0000000121885934 Department of Paediatrics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
44 https://ror.org/01ryk1543 grid.5491.9 0000 0004 1936 9297 Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK
45 grid.430506.4 0000 0004 0465 4079 National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
46 grid.416167.3 0000 0004 0442 1996 Mount Sinai South Nassau, Oceanside, NY USA
47 https://ror.org/02ets8c94 0000 0001 2296 1126 Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN USA
48 https://ror.org/05g3dte14 grid.255986.5 0000 0004 0472 0419 Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine, Tallahassee, FL USA
49 Association of Diabetes Care & Education Specialists, Chicago, IL USA
50 https://ror.org/00f2yqf98 grid.10423.34 0000 0000 9529 9877 Medical Psychology, Hannover Medical School, Hannover, Germany
51 https://ror.org/05fxhrw65 grid.421003.4 0000 0004 0412 0827 Endocrine Society, Washington, DC USA
52 grid.21925.3d 0000 0004 1936 9000 Division of Pediatric Endocrinology and Diabetes, University of Pittsburgh, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA USA
53 Department of Pediatrics, Kristianstad Hospital, Kristianstad, Sweden
54 https://ror.org/04v54gj93 grid.24029.3d 0000 0004 0383 8386 Department of Pediatrics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
55 https://ror.org/05f950310 grid.5596.f 0000 0001 0668 7884 Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium
56 https://ror.org/01vx35703 grid.255364.3 0000 0001 2191 0423 Department of Family Medicine, Brody School of Medicine, East Carolina University, Greenville, NC USA
57 grid.214458.e 0000000086837370 Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI USA
58 https://ror.org/0153tk833 grid.27755.32 0000 0000 9136 933X Center for Public Health Genomics, University of Virginia, Charlottesville, VA USA
59 https://ror.org/02y3ad647 grid.15276.37 0000 0004 1936 8091 Department of Pediatrics, University of Florida, Gainesville, FL USA
60 grid.512756.2 0000 0004 0370 4759 Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY USA
61 https://ror.org/02ets8c94 0000 0001 2296 1126 Division of Pediatric Endocrinology and Diabetology, Herman B Wells Center for Pediatric Research, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN USA
62 https://ror.org/02dgjyy92 grid.26790.3a 0000 0004 1936 8606 Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL USA
63 https://ror.org/01hcyya48 grid.239573.9 0000 0000 9025 8099 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH USA
64 https://ror.org/00j9bjx58 NIHR Clinical Research Network Thames Valley and South Midlands, Oxford, UK
65 https://ror.org/0464eyp60 grid.168645.8 0000 0001 0742 0364 Division of Endocrinology and Diabetes, Baystate Children’s Hospital and University of Massachusetts Chan Medical School - Baystate, Springfield, MA USA
66 grid.412326.0 0000 0004 4685 4917 Research Unit of Clinical Medicine, Department of Pediatrics, Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland
67 https://ror.org/01b6kha49 grid.1042.7 0000 0004 0432 4889 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC Australia
68 https://ror.org/005bvs909 grid.416153.4 0000 0004 0624 1200 Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, VIC Australia
69 grid.17063.33 0000 0001 2157 2938 Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
70 grid.443867.a 0000 0000 9149 4843 Department of Pediatric Endocrinology, Rainbow Babies and Children’s Hospital, University Hospitals Cleveland Medical Center, Cleveland, OH USA
24 6 2024
24 6 2024
2024
67 9 17311759
© American Diabetes Association and European Association for the Study of Diabetes 2024, corrected publication 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk of (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb+; (2) when people who are IAb+ are initially identified there is a need for confirmation using a second sample; (3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care.

Graphical Abstract

Supplementary Information

The online version contains peer-reviewed but unedited supplementary material including a slideset of the figures for download, available at 10.1007/s00125-024-06205-5.

Keywords

Autoantibodies
Glucose monitoring
Prevention
Type 1 diabetes
issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcOverview

Currently, screening of individuals for islet autoantibodies is undertaken as part of programmes to detect children, adolescents and adults who are at higher risk of developing type 1 diabetes due to having a first-degree relative with type 1 diabetes or having a known high-risk HLA genotype. Periodic monitoring of people who have screened positive for one or more autoantibodies (islet autoantibody-positive [IAb+] individuals) is largely, but not always, conducted within these cohort studies. However, up to 90% of people who develop type 1 diabetes are not part of at-risk groups. Thus, screening programmes within the general population are being initiated and guidance for monitoring in non-specialist settings is urgently needed. The guidance provided here was developed by a series of expert working groups, convened as part of a JDRF initiative to document the aims, scope and purpose of monitoring for children, adolescents and adults with islet autoantibody positivity, along with recommended frequencies of monitoring and actions for healthcare professionals (HCPs) when risk of progression towards symptomatic type 1 diabetes is high. This includes expert clinical advice for educational and psychosocial support for IAb+ individuals, including for their families and caregivers. The expert clinical advice for adults reflects available data, yet it is important to note that there are very limited data in adults aged 45 years and older who are IAb+. It is also important to note that this consensus document does not encompass screening for islet autoantibodies, and only provides expert clinical advice for monitoring of individuals who have screened positive for at least one islet autoantibody.

Introduction and rationale

The presence of islet autoantibodies for a presymptomatic period of variable duration in first-degree relatives of individuals with type 1 diabetes has been known for more than 40 years [1], with recommendations for islet autoantibody screening appearing soon after [2]. Decades of subsequent research and monitoring of individuals with islet autoantibody positivity has led to the paradigm shift that type 1 diabetes is a continuum of stages, from genetic risk through to autoimmunity and then metabolic disease. This has been accompanied by the evolution of descriptive terminology that reflects these stages (Table 1). Similarly, treatment options have moved on from monitoring and managing metabolic disease to include options for modulating the autoimmune response [3, 4]. Table 1 Staging criteria for autoantibody-positive individuals in pre-stage 1 and stage 1–3 type 1 diabetes [16–18]

Stage of T1D	Islet autoantibody status	Glycaemic status	Symptoms	Insulin required	
At-risk (pre-stage 1 T1D)	Single autoantibody or transient single autoantibody	• Normoglycaemia

• FPG <5.6 mmol/l (<100 mg/dl)

• 120 min OGTT <7.8 mmol/l (<140 mg/dl)

• HbA1c <39 mmol/mol (<5.7%)

	No symptoms	Not required	
Stage 1 T1D (also referred to as early-stage T1D or presymptomatic T1D)	≥2 autoantibodies	• Normoglycaemia

• FPG <5.6 mmol/l (<100 mg/dl)

• 120 min OGTT <7.8 mmol/l (<140 mg/dl)

• HbA1c <39 mmol/mol (<5.7%)

	No symptoms	Not required	
Stage 2 T1D (also referred to as early-stage T1D or presymptomatic T1D)	≥2 autoantibodiesa	Glucose intolerance or dysglycaemia not meeting diagnostic criteria for stage 3 T1D, with at least two of the following, or meeting the same single criteria at two time points within 12 months:

• FPG 5.6–6.9 mmol/l (100–125 mg/dl)

• 120 min OGTT 7.8–11.0 mmol/l (140–199 mg/dl)

• OGTT values ≥11.1 mmol/l (≥200 mg/dl) at 30, 60 and 90 min

• HbA1c 39–47 mmol/mol (5.7–6.4%) or longitudinal ≥10% increase in HbA1c [66, 67] from the first measurement with stage 2 T1D

• CGM values >7.8 mmol/l (>140 mg/dl) for 10% of time over 10 days’ continuous wear [73]b, and confirmed by at least one other non-CGM glucose measurement test listed

	No symptoms	Not required	
Stage 3 T1D	≥1 autoantibody	Persistent hyperglycaemia with or without symptoms, as measured and confirmed by one or more of the following:

• one random venous glucose ≥11.1 mmol/l (≥200 mg/dl) with overt symptoms

• 120 min OGTT ≥11.1 mmol/l (≥200 mg/dl) and/or

• two random venous glucose ≥11.1 mmol/l (≥200 mg/dl) and/or

• FPG ≥7.0 mmol/l (≥126 mg/dl) and/or

• laboratory-tested HbA1c ≥48 mmol/mol (≥6.5%)

• CGM values >7.8 mmol/l (>140 mg/dl) for 20% of time over 10 days’ continuous wear [73]b and confirmed by at least one other non-CGM glucose measurement test listed

	May includec:

• Polyuria

• Polydipsia

• Weight loss

• Fatigue

• DKA

	+/- Insulin, based on glycaemic status	
aSome people with confirmed persistent prior multiple autoantibody positivity may revert to single autoantibody status or negative status [95]

bCGM is ideally blinded and must be applied and interpreted by a trained HCP. Note, use of CGM-derived criterion did not achieve consensus within the consensus panel and CGM metrics are not part of current ADA or ISPAD guidelines on staging criteria in type 1 diabetes [16, 155]

cStage 3 might not include symptoms

FPG, fasting plasma glucose; T1D, type 1 diabetes

Screening programmes have developed to the point that large numbers of children and adults at risk of and with early-stage type 1 diabetes have been intensively followed in longitudinal cohort studies [5–15] centred on understanding the natural history of progression to symptomatic type 1 diabetes (see Table 2 for a list of studies available for participation). Of note, many entry criteria for individuals with presymptomatic type 1 diabetes into these studies require a family history of type 1 diabetes or HLA genetic risk, and most are focused on paediatric populations. Based on the outcomes of these and other studies, stages of presymptomatic and symptomatic type 1 diabetes are now clinically defined (Table 1) to a degree of clinical consensus [16–18], although regulatory agencies and research studies may differ in definitions. Using these classifications, individuals can be monitored, diagnosed with diabetes and even, at times, started on insulin replacement therapy early in the disease course, based on meeting American Diabetes Association (ADA) [18], International Society for Pediatric and Adolescent Diabetes (ISPAD) [16] or American Association of Clinical Endocrinology (AACE) [19] diagnostic criteria. To date, the ISPAD guidelines have provided metabolic and autoantibody monitoring recommendations for children with presymptomatic type 1 diabetes [16], but do not make specific recommendations for education or psychosocial support in IAb+ individuals, monitoring of single IAb+ individuals or when to start insulin. The Fr1da study has suggested and introduced specific recommendations for children [20]. A separate set of recommendations based on a Delphi-survey of expert opinion has provided guidance on metabolic and autoantibody monitoring, with recommendations for education and psychosocial support, but does not specifically address adults with early-stage type 1 diabetes [21]. Consequently, to date there is no available guidance on monitoring in adults or in individuals with single islet autoantibody positivity, or on when insulin therapy is indicated. Table 2 Established population-based screening and monitoring studies in early-stage type 1 diabetes

Acronym	Study name/description	
ASK	Autoimmunity Screening for Kids programme [7]	
BABYDIAB	Part of the international Type 1 Data Intelligence (T1DI) project [156]	
DAISY	Diabetes Autoimmunity Study in the Young [6]	
DIPP	Type 1 Diabetes Prediction and Prevention Study based in Finland [11]	
DPT-1	Diabetes Prevention Trial–Type 1 [12]	
ENDIT	European Nicotinamide Diabetes Intervention Trial [13]	
Fr1da	Population-based healthcare research study based in Bavaria, Germany [9]	
INNODIA	Global partnership between academic institutions, commercial partners and patient organisations [14]	
PLEDGE	Population Level Estimation of T1D Risk Genes in Children [155]	
TEDDY	The Environmental Determinants of Diabetes in the Young study [5]	
Type 1 Diabetes TrialNet	International research network centred on delaying or preventing T1D [10]	
Type1Screen	Australian screening and monitoring programme open to relatives of individuals with type 1 diabetes and IAb+ people identified through other screening pathways (ANZCTR registration no. ACTRN12620000510943)	
Note that major research networks are included in the table, but this is not an exhaustive list

ANZCTR, Australian New Zealand Clinical Trials Registry

Consensus on evidence-based expert clinical advice for monitoring is an important unmet need since a positive test for islet autoantibodies (Table 3) is a condition for access to disease-modifying therapies, such as teplizumab [22]. In addition, islet autoantibody screening is anticipated to become more common [7, 23–25], highlighting the need for clear monitoring advice. Table 3 Autoantibodies against islet autoantigens detected in stage 1–3 type 1 diabetes

Autoantibody	Islet specificity	Typical characteristics	
IAA	Insulin	• Common as a first detected autoantibody in young children [157, 158]

• Appearance is more common in younger children [159]

• Frequency of appearance declines with age

• Not informative for individuals treated with insulin, who often develop antibodies in response to injected insulin

	
GADA	GAD	• Common as a first detected autoantibody in childhood, up until age 15 years [157, 158, 160]

• Adult-onset cases most often present with GADA [161]

• Is associated with slower progression to T1D [162] and is often found as a single positive islet autoantibody, especially in adults

	
IA-2A (also known as ICA512)	Tyrosine phosphatase islet antigen-2	Presence is associated with more-advanced islet autoimmunity and faster progression to stage 3 T1D [55, 163]	
ZnT8A	Zinc transporter type 8, a transmembrane protein in the beta cell granule	Presence can improve risk stratification in individuals with single GADA+, IAA+ or IA-2A+ status [164]	
ICA	Multiple antigens, undefined	Detected by indirect immunofluorescence on islet cell tissue. While not frequently measured other than in research studies, it does add to risk determination in the presence of other biochemical autoantibodies	
IA-2A, insulinoma antigen-2 autoantibody; ICA512, islet cell autoantigen 512; T1D, type 1 diabetes

Screening efforts are identifying an ever-growing number of IAb+ people who warrant education and ongoing monitoring for progression towards clinical diabetes. Evidence shows that such monitoring in research studies can significantly reduce the incidence of diabetic ketoacidosis (DKA) at diagnosis [24, 26–33], occurring in up to 70% of unmonitored individuals, which is greatly lowered for individuals participating in follow-up studies [26, 34–39]. The impact of monitoring in general clinical practice on DKA rates is not known. DKA is a life-threatening condition that requires hospital admission, with significant associated costs for critical care [40–42]. Additionally, in a number of studies, DKA at presentation of type 1 diabetes in youths has been associated with higher HbA1c that was sustained for up to 11 years after diagnosis [43–45]. Other studies have, however, not found such an association between DKA at presentation of type 1 diabetes and higher long-term glycaemic levels [46]. The lack of DKA at onset of type 1 diabetes is also predictive of fewer severe hypoglycaemic events 10 years after diagnosis [47]. In this context, the overall goals of monitoring are described in Table 4. Table 4 Purpose of monitoring in IAb+ children, adolescents and adults

1. Primary purpose is to prevent DKA and to minimise the risk of requiring emergency care or hospital admission	
2. Identification for and monitoring of therapeutic intervention(s) to delay stage 3 T1D onset (where available) and prolong beta cell function	
3. To provide advice for the start of insulin in stage 3 T1D, when glucose is sufficiently elevated and before symptoms develop, to optimise HbA1c and avoid the consequences of hyperglycaemia on long-term glycaemic outcomes	
4. To avoid misdiagnosis of T2D and delayed commencement of insulin therapy	
5. Referral for participation in research studies	
T1D, type 1 diabetes; T2D, type 2 diabetes

Monitoring of people with islet autoantibody positivity outside of research settings will require expert clinical advice that is clear and actionable by HCPs who have limited expertise in diabetes. As indicated, current insights into monitoring progression to clinical type 1 diabetes are largely derived from research studies of individuals known to be at risk of type 1 diabetes, and general population data are less extensive. With this caveat, knowledge on best practices is particularly important for primary-care and secondary-care physicians who may not frequently see people known to be at risk of type 1 diabetes, and yet who will be tasked with the initial aspects of monitoring following a positive autoantibody screen. Other people who may assist with care of these individuals will include nurse practitioners, physician assistants, diabetes care and education specialists (DCES), psychologists and other mental and behavioural health professionals, all of whom have a role in supporting IAb+ individuals and their families within the monitoring environment. Clear expert clinical advice for monitoring by these groups of HCPs increases the likelihood that individuals at risk for or in early stages of type 1 diabetes, and their families, can receive accurate and actionable education about presymptomatic type 1 diabetes and their individual status.

The requirement for monitoring

Islet autoantibodies against four major pancreatic autoantigens are currently clinically available; these consist of IAA, GADA, insulinoma antigen-2 autoantibody (IA-2A; also called islet cell autoantigen 512 [ICA512]) and ZnT8A [48]. These are often considered ‘biochemical autoantibodies’ and are the screening targets recommended by the most-recent ADA Standards of Care [25]. A further islet autoantibody assay, for ICA, using indirect immunofluorescence on pancreatic tissue, has been used for screening purposes, but it is less available outside of research studies and the antigenic targets are not fully known. Considerable evidence in multiple populations supports the concept that the number and type of biochemical autoantibodies can be used to predict risk for progression to clinical disease (stage 3 type 1 diabetes; see Table 1). These autoantibodies and their characteristics are described in Table 3. However, it must be noted that these attributes are derived from observations made in known IAb+ populations in the research environment. Further data from studies in IAb+ groups in the general population are needed.

Confirmation of IAb+ status is important to identify the persistence of the underlying autoimmune response and the validity of the target antigen, although the accuracy of autoantibody tests can vary between laboratories and between target antigens. Therefore, the first positive test should be confirmed with a second test within 3 months [49] and, where possible, in a laboratory that meets the performance standards set by the Islet Autoantibody Standardization Program (IASP) [50]. Persistent IAb+ status on two or more different samples is needed, using sensitive and specific assays with high predictive value for disease progression [51]. Several research programmes have tested for islet autoantibody status using capillary sampling to obtain serum or dried blood spots for assessment; however, venous samples are preferred (due to reduced interference from haemolysis) and should be used as confirmation whenever capillary testing has been performed initially.

Predicting when an individual with type 1 diabetes-related autoantibodies may progress to stage 3 type 1 diabetes is difficult. However, in children and adolescents, persistent multiple IAb+ status confirms early-stage (stage 1 or stage 2) type 1 diabetes with higher rate of progression to stage 3 type 1 diabetes compared with single IAb+ status [52]. For the same reasons as discussed for single IAb+ status, confirmation of multiple IAb+ status is important, as it indicates early-stage type 1 diabetes, and should adhere to the ‘rule of twos’, i.e. the presence of two different autoantibodies, confirmed in two tests from two separate samples [51–54]. Subsequent loss of individual antibodies is not associated with a slower rate of progression. The type of positive autoantibody (Table 3) is also of importance, since, as children age, relative risks for progression with each antibody type will change [55, 56], with some evidence that this is also true for adults [55, 57]. Consideration of these data, along with autoantibody titres, may aid risk stratification [58]. Although fewer data are available in adults, Type 1 Diabetes TrialNet cohort data indicate that the rate of progression to type 1 diabetes in IAb+ adults is slower than in children [59].

Misdiagnosis of type 1 diabetes as type 2 diabetes in adolescents and adults can lead to DKA [60], as this misdiagnosis means that these individuals are often not started on insulin [61]. Latent autoimmune diabetes of adults (LADA) can also be misdiagnosed as type 2 diabetes [62], with a risk of delayed insulin initiation. These observations emphasise the value of autoantibody testing for newly-diagnosed adults with diabetes, particularly when they have features of type 1 diabetes (e.g. younger age, non-obese, sudden weight loss, mild acidosis, DKA, hyperglycaemia >16.7 mmol/l [>300 mg/dl]) [63], for making an accurate diagnosis and starting appropriate treatment. It is, however, important to recognise that some individuals with new-onset type 1 diabetes have a phenotype that does not differ substantially from people with type 2 diabetes, particularly given the increased prevalence of obesity [60, 64]. Misdiagnosis of MODY is also reported [65], suggesting that islet autoantibody screening can be valuable at presentation of all forms of diabetes.

An important outcome of monitoring individuals with islet autoantibody positivity is to inform the decision to initiate insulin therapy, and this is an area of evolving practice. In some centres, individuals with hyperglycaemia (see Table 5) but with HbA1c <48 mmol/mol (<6.5%) might not be started on insulin without the presence of symptoms. Sequential HbA1c monitoring has been productive in this context in paediatric studies on individuals with islet autoantibody positivity, since an absolute ≥10% increase from baseline, even if the HbA1c test reading stays below 48 mmol/mol (6.5%), is predictive of disease progression [66, 67] within a median of 1 year. Risk of progression within 2 years following a confirmed ≥10% increase in HbA1c is lower for older individuals. This aspect of stage 3 type 1 diabetes (i.e. when to start insulin once hyperglycaemia is confirmed) requires further evidence to support clinical practice, to better understand the metabolic and mental-health outcomes. Table 5 Attributes of current monitoring methods

Method	Pros	Cons	Metrics obtained	
Reference OGTTa	• Gold standard in research settings

• Used to stage disease and predict progression

	• Requires glucose load and 2–5× blood draws over 2 h	• Glycaemic staging

• Risk scores for progression (DPTRS, DPTRS60, Index60, M60, M120, PLS) [94, 165–169]

	
Standard OGTTb	• Similar to test for GDM: OGTT with 2× blood draws (compared with 3× draws in GDM test), performed routinely in clinical care	• Requires 2× blood draws: fasting and at 2 h	• 120 min OGTT-derived glucose

• M120

	
Random glucose	• One-off sample

• Low cost

	• Requires a blood draw or fingerstick test

• Less sensitive than 120 min OGTT

	• Similar to 120 min OGTT-derived glucose [96] if obtained 2 h postprandially	
Standard HbA1c test	• Highly specific for clinical diagnosis of stage 3 T1D

• Can use capillary sample

• Longitudinal HbA1c may be as informative as OGTT [66]

	• Indicates 3 month mean glucose. Often normal in asymptomatic or recent-onset stage 3 T1D

• May be affected by age, non-diabetes disease states (e.g. renal, haematological syndromes)

• Not suitable in the home setting

	• Risk of progression to ‘clinical disease’: HbA1c >39 mmol/mol (>5.7%) [170]

• 10% rise from baseline (at first positive islet autoantibody) over 3–12 months [66, 67], suggests dysglycaemia and progression to stage 2 T1D

• Consider use of CGM if 10% rise in HbA1c is confirmed, or higher frequency of SMBG, to monitor risk for progression

	
CGMc	• Can be used at home

• Can be blinded for physician review only in some regions

• Optimal duration of CGM wear is validated in adults and children >2 years of age with diagnosed T1D, at all glycaemic levels [171]

	• Risk of anxiety for unblinded user seeing CGM fluctuations and experiencing alarms

• Requires appropriate education on use and interpretation

• Many primary-care HCPs are unfamiliar with interpretation

• Cost and access issues

• Duration of wear not validated in early-stage T1D

	• Sensitive in detecting individuals with asymptomatic stage 3 T1D and dysglycaemia in stage 2 T1D [73]

• Risk of progression to ‘clinical disease’, i.e. 10% of time with glucose >7.8 mmol/l (>140 mg/dl) has been associated with an 80% risk of progression to T1D within 12 months [72]

• ≥5% time with glucose ≥7.8 mmol/l (≥140 mg/dl) has been associated with a 40% risk of progression to T1D within 2 years [71]

• Other PPV metrics not tested

	
SMBG	• Simple to use at home

• Comparatively low cost

	• Uncomfortable for users, can affect accuracy and use

• Optimal timing and frequency have not been determined

	• Immediate capillary blood glucose test result

• 2 h postprandial measure likely of most value

	
C-peptide	• Validated measure of beta cell function

• Stimulated C-peptide in research settings is valuable to assess insulin production and distinguish between T1D (or stages of T1D) and T2D

	• Can be falsely low in hypoglycaemia <3.9 mmol/l (<70 mg/dl), in severe hyperglycaemia/DKA or after fasting, so concomitant serum glucose should be checked for interpretation

• Wide range of values at clinical diagnosis, including >0.2 nmol/l, and persistent, but low, levels of secretion can be seen long after diagnosis

• Presence of C-peptide does not exclude T1D and on its own is not useful for staging or diagnosis of T1D

	• A stimulated postprandial C-peptide value ≤0.2 nmol/l with IAb+ status can assist with appropriately classifying diabetes type	
Repeat antibody testing	• Confirms initial IAb+ test result and progression to multiple IAb+ status	• None	• Autoantibody type and single IAb+ or multiple IAb+ status	
Education	• Provides awareness of diabetes symptoms and signs	• None	• Person-reported outcomes for possible progression to stage 3 T1D	
aUsed in research settings for staging progression of impaired glucose tolerance as C-peptide provides important predictive value

bUsed in clinical practice to detect impaired glucose tolerance in prediabetes and gestational diabetes mellitus

cUse of CGM-derived criterion did not achieve consensus within the consensus panel, with further evidence required to confirm findings to date

DPTRS, Diabetes Prevention Trial-Type 1 risk score; GDM, gestational diabetes mellitus; M60, 60 min test result; M120, 120 min test result; PLS, partial least squares; PPV, positive predictive value; T1D, type 1 diabetes; T2D, type 2 diabetes

What should be monitored?

It is acknowledged that the practice of monitoring of individuals with islet autoantibody positivity must accommodate different settings with diverse healthcare resources. In this context, there are multiple available tools for monitoring, including self-monitored blood glucose (SMBG), periodic continuous glucose monitoring (CGM), a standard OGTT, random venous glucose, HbA1c and repeat islet autoantibody monitoring. In this context, serial stimulated C-peptide measurement during an OGTT can be used to assess deterioration of beta cell function and to predict risk development of type 1 diabetes [68]. Since individuals who present with clinical type 1 diabetes (stage 3) often have significant residual beta cell function [69], they may benefit from therapies that can optimise prolongation of insulin secretion [70].

The pros and cons of each monitoring method are documented in Table 5. Identification of an increase in sequential HbA1c values from a baseline reading can be as informative as 2 h OGTT values in predicting risk of stage 3 type 1 diabetes in youth with genetic risk and type 1 diabetes-associated autoantibodies [66, 67]. Ongoing research continues to evaluate the role of CGM (including professional CGM, which is blinded to the user) in aiding in the identification of individuals, including those with a normal OGTT, who are likely to rapidly progress to stage 3 type 1 diabetes [71–73]. To date, use of CGM metrics in individuals who have multiple IAb+ status has been shown to be predictive of progression to type 1 diabetes, but CGM measures are not yet as sensitive as OGTT testing [74].

Where should monitoring take place?

In practice, monitoring should be carried out wherever the skills and resources exist to perform the appropriate tests (Table 5). However, since many people will be monitored in primary care, there is a need to consider different intensities of monitoring consistent with resources available. The capabilities of primary-care HCPs and other care providers should be applied to monitoring of early-stage type 1 diabetes without the need to refer to an expert practitioner, until clinically appropriate. In primary care, this may help specify basic education about symptoms and glycaemic signposts. It is understood that, compared with stage 1, monitoring in stage 2 type 1 diabetes may require more-expert practitioners.

Objectives and methodology

The aim of this international consensus report is to formulate expert clinical advice, based on current evidence and expert opinion, that specifies the required monitoring and management approach for people who have been identified as having IAb+ status and pre-stage 3 type 1 diabetes, and can be used in daily clinical practice. Overall, these key principles should encompass: (1) who should be monitored; (2) which endpoints to monitor; (3) the frequency and duration of monitoring; (4) initiation of insulin during stage 3 type 1 diabetes; and (5) how to provide psychosocial and educational support for affected individuals and families.

We acknowledge that monitoring of IAb+ individuals will occur in diverse settings, with variable resources to support effective monitoring of IAb+ individuals. Thus, a guiding principle of this consensus report is to provide advice that is straightforward and actionable within the landscape of available clinical skills and resources, wherever the monitoring will take place. The audience for this consensus document, therefore, includes: (1) primary-care providers; (2) endocrinologists and diabetologists; (3) DCES; (4) mental and behavioural health professionals; and (5) individuals at risk for or in early stages of type 1 diabetes and their families.

Methodology

The consensus process was initiated by the JDRF with a conference held on 21 February 2023 at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Berlin, Germany, with in-person or virtual attendance. MP served as Chair of the project and LAD served as Vice Chair. A mission statement was created and the attendees were invited by email from JDRF and the consensus project leadership. The initial working group comprised 61 internationally recognised physicians, nurse practitioners, clinical psychologists and DCES, with expertise in the diagnosis and care of people with early-stage type 1 diabetes. The conference was centred on monitoring of IAb+ people in early-stage type 1 diabetes, including discussions of current guidance on current best practice for monitoring, as applied by several prospective type 1 diabetes prevention trials (discussed in detail below).

Following a moderated discussion, expert participants were offered the opportunity to join at least one of four working groups, each focused on key aspects of monitoring. Each working group was chaired by two expert contributors, as noted below, and was tasked with self-organised review of the available evidence, participation in serial online discussions and development of core principles. The working groups were: (1) monitoring in children and adolescents (Chairs: REJB and KJG); (2) monitoring in adults (Chairs: RS-R and JMW); (3) educational needs (Chairs: KJB and BIF); and (4) psychosocial interventions (Chairs: KAD and LBS). This subsequently generated 21 separate online group discussions. Each aspect of these discussions was documented with support from JDRF team members and a medical writer. It must be noted that this document is not intended or structured as a systematic review.

On a weekly basis, from 3 May 2023 onwards, evidence-based statements and expert interpretations were drafted for review and revision. At the end of this iterative process, an agreed narrative review of the available evidence was compiled along with the expert clinical advice. Each bulleted principle was assigned a level of supporting evidence (A, B, C or E; see electronic supplementary material [ESM] Table 1) that adheres to the evidence-grading system for ‘Standards of Care in Diabetes—2023’, published by the ADA [75]. The process concluded with a conference to review and endorse the penultimate consensus report at the ADA’s 83rd Scientific Sessions in San Diego, CA, USA. Following this meeting, a revised draft was made available for public comment, after which the consensus document was finalised. The outcomes of this process are also summarised in an algorithm that details the decision path for monitoring of IAb+ people regardless of whether they were screened as part of a research protocol or in the clinical setting for any reason (Fig. 1).Fig. 1 Algorithm for monitoring of people screened positive for one or more islet autoantibodies. aMonitoring frequency and methodology depends on age, length of time since first detection of islet autoantibody, number of islet autoantibodies detected and presence of symptoms of type 1 diabetes (see Tables 1, 3, 4 and 5). Ab, antibody; GP, general practitioner; PRN, pro re nata (as needed); Sx, symptoms; T1D, type 1 diabetes. This figure is available as part of a downloadable slideset

1. Terminology

Precise and consistent language is important to facilitate clear communication and education. As the field has evolved, so has the language around multiple IAb+ status, the stages of type 1 diabetes and associated risk of progression. It was once commonplace to refer to ‘risk of’ and ‘prevention of’ type 1 diabetes in individuals with multiple IAb+ status. However, the staging criteria recognise seroconversion to multiple IAb+ status as the onset of early-stage type 1 diabetes and, thus, it is not possible to both have a condition and be ‘at risk’ for it.

Therefore, stage 1 type 1 diabetes and stage 2 type 1 diabetes (Table 1) should be referred to by their defined names or collectively referred to as ‘early-stage type 1 diabetes’. While the staging criteria are still becoming widely known, it may be appropriate to refer to these stages as ‘presymptomatic type 1 diabetes’ for some audiences, to highlight that these early stages exist prior to traditional, symptomatic (i.e. stage 3 type 1 diabetes) disease. Individuals with a genetic risk (based on genetic screening and/or family history) or with only single IAb+ status have pre-stage 1 type 1 diabetes and can be referred to as ‘at risk’, but individuals with multiple IAb+ status are confirmed as having early-stage type 1 diabetes. It must also be clear what the focus of prevention is; for example, prevention of seroconversion, progression to dysglycaemia or of stage 3 type 1 diabetes.

2. Partnership between primary-care and specialist HCPs

There is a need for primary care to take on some of the early-stage monitoring and managing IAb+ children and adults. However, staging criteria are relatively new and are unlikely to be widely known among primary-care HCPs. Therefore, educational steps and materials must facilitate the partnership between primary-care HCPs and secondary care. Primary-care HCPs in some regions (e.g. the USA, Europe) are involved in screening and monitoring tasks for hypercholesterolaemia and other metabolic syndromes, so the expectation is that this is possible for early-stage type 1 diabetes. A critical need is that all HCPs recognise that some IAb+ individuals can progress rapidly, whereas others may not develop symptoms for decades. In this context, the following expert clinical advice is suggested:

3. Monitoring in children and adolescents

The current landscape of monitoring children and adolescents in early-stage type 1 diabetes

The following section encompasses monitoring of children and adolescents aged up to 17 years. The overall algorithm is summarised in Fig. 1. For a young person who has screened positive for multiple IAb+ status, monitoring recommendations are also provided by the ISPAD [16] and the Fr1da study [20].

This expert clinical advice emphasises the need to benchmark the glycaemic stage of disease and to offer ongoing monitoring for disease progression, which should be appropriate to the needs of the affected person and their family. At present, standard 2 h OGTT (1.75 g of glucose per kg of body weight up to 75 g maximum) is the preferred modality, particularly for inclusion in research studies, whereas less-intensive methods are suggested for children or adolescents who decline to undertake OGTT or participate in a research protocol. Even in a clinical-study setting, adherence with OGTT monitoring can be low [76]. Given the diverse settings and resources available, amongst the monitoring tools identified (Table 5), HbA1c testing is not suitable outside of the clinical setting and only random glucose assessments, routine SMBG and CGM, that do not require venipuncture, can be self-managed at home. Studies using CGM in small cohorts of children and youth with stage 1 or stage 2 type 1 diabetes have suggested that glucose levels ≥7.8 mmol/l (≥140 mg/dl) for >10% of each day is associated with an 80% risk of progression to type 1 diabetes within 12 months of the CGM assessment period [72, 77]. In this context, risk of progression to stage 3 type 1 diabetes within 2 years of baseline CGM assessment was 40% in individuals with early-stage type 1 diabetes who spent ≥5% of each day with glucose ≥7.8 mmol/l (≥140 mg/dl) [71]. These outcomes indicate a need for more evidence to confirm the emerging value of CGM in monitoring individuals with early-stage type 1 diabetes and to understand the disease-predictive value of additional CGM metrics. This need is more pressing given that home use of CGM systems and CGM-derived glycaemic metrics is being evaluated for risk stratification for healthy relatives of people with type 1 diabetes [78, 79].

Monitoring at a 6–12 monthly cadence has been used for participants in prevention trials, depending on risk stratification. More-frequent monitoring can be indicated for children who screen positive for islet autoantibodies before 3 years of age and are at high risk of progression [24, 51], for example, at 3- to 6-monthly intervals, depending on staging [24]. It should be noted that, amongst monitoring tools, not all CGM systems are generally available in all regions, or for use in very young children. For all individuals outside of the research setting, reducing the frequency of monitoring can be considered as part of a minimally burdensome approach and modelling studies suggest this can be achieved while meeting the goal of DKA prevention on a population level [80]. In this context, youths of Black race and/or Hispanic ethnicity are less likely to participate with monitoring [81].

Monitoring for single IAb+ at-risk children

Evidence from cohort studies indicates that up to 50% of children with single IAb+ status revert to being islet autoantibody negative (IAb−) [82, 83]. Children with confirmed persistent single IAb+ status are not at high risk for progression compared with those with multiple IAb+ status, with one population-based study indicating that the 10 year risk of progression to type 1 diabetes for persistent single IAb+ children is 14.5%, with most of that progression (10%) happening in the first 2 years after becoming IAb+ [51]. This analysis also showed that the progression rate is higher for young children who have single IA-2A positivity (40.5%), compared with GADA positivity (12.9%) or IAA positivity (13.1%) [51]; however, it must be noted that fewer than 10% of children with single IAb+ status are IA-2A+. Younger age (<5 years) at first single-confirmed islet autoantibody positivity is a risk factor for progression to multiple islet autoantibody positivity, particularly during the first 2 years after seroconversion [84, 85]. As children age, relative risks for progression with each antibody subtype changes [56], with an increased effect for GADA with increasing age and a reduced effect for IAA [86].

For young children, evidence indicates that metabolic and autoantibody monitoring frequency in the first 2 years after first detection of an autoantibody is key, as this is when spread from at-risk single islet autoantibody positivity to early-stage type 1 diabetes with multiple islet autoantibody positivity is most likely. Following confirmed single IAb+ status, the IAb+ evolution after 2 years predicts development of clinical type 1 diabetes [87]. Progression to multiple IAb+ status or reversion is also highest in the first 2 years in single IAb+ pre-school children, with a hazard rate of 0.3 in the first 2 years vs 0.05 for children who have been single IAb+ for >2 years [84]. Among children with increased genetic risk, those who remain single IAb+ have a risk for type 1 diabetes of 1.8 per 100 person-years, children who revert to negative status have a risk of 0.14 per 100 person-years and children who have never been IAb+ have a risk of 0.06 per 100 person-years [83]. The rate of progression to multiple IAb+ status also declines with age [88].

Limitation

Many data on single IAb+ children are derived from groups with extended prospective follow-up and known genetic risk profiles or first-degree relatives with type 1 diabetes with limited racial/ethnic diversity. Data on individuals in the general population are more limited, particularly in those with a single screening event.

Monitoring for multiple autoantibody-positive children (early-stage type 1 diabetes)

Children with confirmed multiple IAb+ status are at very high risk for progression to stage 3 type 1 diabetes within 15 years. Combined data from five prospective studies indicate that the 15 year risk for stage 3 type 1 diabetes is 85% for children with two islet autoantibodies and 92% for those with three islet autoantibodies, and that there is a >99% lifetime risk [87]. In children with multiple islet autoantibody positivity, younger age at first islet autoantibody detection predicts more-rapid progression to stage 3 type 1 diabetes [51, 93]. Although data on children with multiple islet autoantibody positivity identified from general population screening are derived from shorter follow-up durations, progression rates appear to be similar to those observed in relatives of individuals with type 1 diabetes enrolled in longitudinal research cohort studies [24, 94].

The detection of multiple autoantibodies should be confirmed in a venous sample, within 3 months [49]. However, this should not be a rate-limiting step in the monitoring or treatment process, as progression can happen rapidly in young children. Confirmation is critical, since without it there is a risk of delivering a false diagnosis of multiple IAb+ status, with consequent anxiety and distress for the individual. Conversely, although loss of confirmed multiple IAb+ status is rare and may be associated with reduced risk of progression to type 1 diabetes [95], monitoring should not be discontinued in this group.

Expert clinical advice for monitoring of multiple IAb+ children (early-stage type 1 diabetes)

Monitoring of glucose metabolism among children with multiple IAb+ status is necessary to predict time to stage 3 diagnosis, identify those who may be eligible for intervention and prevent DKA. Options for metabolic assessments include home SMBG monitoring, periodic CGM assessment, and laboratory testing for HbA1c, random venous or capillary blood glucose and OGTT (with stimulated C-peptide assessments). It is acknowledged that there is variable access to high-quality laboratory-testing facilities outside of the research setting. Where possible, the opportunity to undertake monitoring at home or in the primary-care setting should be considered (Table 5).

4. Monitoring in adults

The current landscape of monitoring adults who are at risk of or have early-stage type 1 diabetes

The following guidance encompasses monitoring of adults aged 18 years and over, although the advice is based on outcome data that typically reflect adults younger than 45 years of age. Data specific to adults older than this are an important unmet need. Epidemiological data show that, overall, type 1 diabetes is diagnosed more frequently in adulthood than in childhood [98–101], at a median of more than 35 years of age [102, 103]. Despite this, misdiagnoses of type 1 diabetes in adults remain common and are increasingly likely with age [60], setting the scene for development of DKA. In common with childhood-onset type 1 diabetes, adult-onset type 1 diabetes is associated with the presence of islet-specific autoantibodies [104–107]. Although TrialNet cohort data indicate that the rate of progression to type 1 diabetes in IAb+ adults is slower than in children, many adults with multiple IAb+ status and early-stage type 1 diabetes still develop stage 3 disease [59]. While it has been suggested that progression in some adults may not occur and that some of those who do progress have only single islet autoantibody positivity, further long-term follow-up data are needed to better characterise the long-term implications of persistent autoimmunity in adults [108]. For example, recent data highlight the frequent presence of islet autoimmunity in cohorts presenting with phenotypic type 2 diabetes [109].

Guidance to inform clinical monitoring practices in adults represents a considerable unmet need. There are many evidence-base gaps, including a lack of information about risk of disease progression in IAb+ adults without a family history of type 1 diabetes, particularly in individuals with non-European ancestry. Data on suggested monitoring protocols, including effectiveness in preventing DKA and adherence with monitoring, are substantially based on children and adolescents. The frequency of DKA among adults at diagnosis with type 1 diabetes is unknown but believed to be lower than for children, given that adults may recognise and respond to symptoms of hyperglycaemia, and often have higher C-peptide levels at clinical diagnosis and a slower decline in beta cell function over time [110]. Yet, incorrect assumptions leading to underdiagnosis of type 1 diabetes in adults mean many develop DKA before starting insulin therapy.

DKA incidence at clinical diagnosis can be reduced by participation in active monitoring [24, 26, 27]. Regarding frequency of monitoring, modelling based on TrialNet data suggest that conducting approximately half the number of visits involved in a research setting (typically once every 12 months rather than every 6 months), is likely to be effective in substantially reducing the incidence of DKA to the levels seen in research studies both for children and adults [80]. However, data from the TrialNet study indicate that adults 18 years and older are less likely than paediatric participants to engage with recommended monitoring using 6–12 monthly OGTT in the early phases after screening positive for autoantibodies [81]. As with youths, adults of Black race and/or Hispanic ethnicity are less likely to participate with monitoring in this context [81].

Most endocrinologists and primary-care HCPs will not be trained in monitoring adults with single IAb+ status or early-stage type 1 diabetes. Thus, the educational need will be significant. As with children and adolescents, monitoring in IAb+ adults must be realistic and actionable across diverse regions, with different resources. HCPs are significantly burdened such that additional tasks for monitoring in pre-stage 3 type 1 diabetes must be clinically useful.

Monitoring for single autoantibody-positive at-risk adults

Frequency of monitoring can be based on the stage at which an individual with islet autoantibody positivity is diagnosed. Single IAb+ adults with dysglycaemia should be monitored more frequently than those with normoglycaemia. Additional risk stratification may also be possible based on other characteristics, such as age, or modifiable factors, such as abdominal obesity.

Monitoring for multiple autoantibody-positive adults (early-stage type 1 diabetes)

As with monitoring in single IAb+ adults, more-frequent monitoring is proposed for individuals with multiple IAb+ status if they are diagnosed with stage 2 type 1 diabetes compared with stage 1 type 1 diabetes. Risk stratification based on age, abdominal obesity and other modifiable factors also applies.

Monitoring during pregnancy for IAb+ women

Evidence on the progression of type 1 diabetes in IAb+ pregnant women is limited and research data on this aspect of managing risk in early-stage type 1 diabetes is a significant unmet need (Table 6). With that said, a high risk for postpartum type 1 diabetes has been indicated [114], and the guidance below is primarily based on expert opinion. Pregnancy demands increased pancreatic beta cell function and may result in diabetes, as it does in gestational diabetes mellitus (GDM) [115]. Given that 60% of babies born to women with diagnosed type 1 diabetes are large for gestational age (LGA), which is associated with increased rates of obstetric and neonatal complications [116, 117], it is important to avoid a missed early diagnosis and promote normal fetal development.

Table 6 Selected unmet needs for further research and clinical development

Unmet research needs	
• Long-term rates of progression to stage 3 diabetes in IAb+ individuals without a family history of T1D, and progression rates in adults and people of non-European ancestry.	
• The impact of pregnancy in women who are IAb+ and the glycaemic changes that may be evident during pregnancy and in the postpartum period, along with risks for progression to stage 3 T1D during and after pregnancy.	
• Neonatal outcomes for infants of women who are IAb+ and the association with glycaemic changes during pregnancy.	
• Cost-effectiveness of monitoring strategies for individuals with early-stage T1D.	
• Timing of insulin initiation in people with presymptomatic T1D, including short- and long-term metabolic and mental-health outcomes of different strategies.	
• Impact of education alone, independent of other monitoring activities, on frequency of DKA at diagnosis and presentation of T1D.	
• Methods of identifying and monitoring behavioural health needs in early-stage T1D.	
Unmet clinical needs	
• Comprehensive and consistent educational materials that use consistent language and vocabulary when referring to diabetes stages and risk, including translation into region-specific languages. This applies to all impacted people, from affected individuals to expert providers.	
• Validated tools to measure the anxiety, depression and other mental-health behaviours that are specific to early-stage T1D.	
• Sufficient availability of mental-health professionals with expertise in T1D, including early-stage T1D in youth and adults.	
• Knowledge and coverage of appropriate monitoring by stakeholders (insurers, clinicians, etc.)	
• Timely access to expert HCPs and centres of expertise for intervention(s) to delay onset of stage 3 T1D.	
The key principles presented in this table and in this consensus document will be subject to updating once additional evidence becomes available

T1D, type 1 diabetes

5. When to start insulin

At some point, monitoring will reveal a person with persistent and/or recurrent hyperglycaemia prompting a decision on whether to start insulin, along with associated education and support for affected individuals and their families. As screening programmes identify more people with early-stage type 1 diabetes, more people are being assessed as meeting classic diagnostic criteria for stage 3 type 1 diabetes (Table 1), but who might not yet require insulin therapy. Decisions about how and when to initiate insulin will be based on a range of factors, many of which do not have a body of evidence. Therefore, consideration of starting insulin should trigger a referral to a specialist centre with expertise in initiating and managing people with type 1 diabetes on insulin.

6. Education

The primary goals of education for the care of IAb+ individuals and their families are outlined in Table 7. Given the paucity of evidence on education for people with early-stage type 1 diabetes, extensive experience in education for stage 3 type 1 diabetes can be extrapolated to this population. National standards for diabetes self-management education and support (DSMES) have been published by the ADA and the Association of Diabetes Care & Education Specialists (ADCES) and are broadly applicable in this context [119]. When appropriate, evidence from studies in stage 3 type 1 diabetes are used to support grading of evidence. Table 7 The primary goals of education for care of IAb+ individuals and their families

1. To prevent DKA and promote safe monitoring practices and reduce the occurrence of symptoms of diabetes	
2. To minimise the requirement for emergency care, hospital admission and need for intensive care at diagnosis of T1D	
3. To improve appropriate risk perception at each monitoring milestone	
4. To understand specific outcomes, e.g. prevention of DKA, initiation of insulin therapy	
5. To understand available interventions	
6. To explore and understand the benefits of individual participation in research studies	
7. To provide education that supports psychosocial interventions to optimise general health and mental health for affected individuals and their families	
T1D, type 1 diabetes

Experience in clinical studies can also inform education for people with early-stage type 1 diabetes and their families/caregivers. The Environmental Determinants of Diabetes in the Young (TEDDY) prospective study protocol emphasises parental education regarding symptoms and signs of diabetes. For families new to type 1 diabetes, this education provides foundational skills for diabetes management that are a component of reduced parenting stress at the time of stage 3 diagnosis compared with individuals who were members of the community control group and did not receive education [120]. Similarly, families of children with early-stage type 1 diabetes in the Fr1da study are invited to participate in an educational programme of blood glucose monitoring and symptoms of hyperglycaemia/DKA. They are also provided with a guidebook specifically designed for children with early-stage type 1 diabetes, and assigned a contact person to answer questions at any time. Children who take part in this programme alongside metabolic monitoring have a lower rate of DKA and reduced HbA1c at stage 3 type 1 diabetes presentation compared with children who declined education and follow-up [33]. Over 50% had no symptoms at the clinical presentation of stage 3 type 1 diabetes, 93.5% had no weight loss and length of stay in hospital was shorter [91, 92].

Basic community awareness campaigns not associated with monitoring and centred on the early symptoms of type 1 diabetes, that target teachers, paediatricians and parents, have been effective in reducing DKA rates in children in regional settings (Parma in Italy [121] and Newcastle in NSW, Australia [122]). However, national campaigns in Italy and Austria, with the same objectives, have not seen the same impact [123, 124]. The content and delivery of these campaigns were not similar, so it is hard to draw conclusions about the effectiveness of this education.

Education topics and intensity for people with early-stage type 1 diabetes and their families should be based on type 1 diabetes stage, age, rate of progression, etc. First-degree relatives may have different needs for support and guidance from the general population, as they have an established awareness of the implications and impact of IAb+ status. Education topics should be linked to specifically timed action plans and include the topics detailed below. Education can be tailored so it is uniquely appropriate for both stage 1 and stage 2 type 1 diabetes (Table 1). Clinical practitioners with experience in early-stage type 1 diabetes should be involved in the later steps of education.

When should education be provided?

The needs for education are centred on the key moments in the life of the person with early-stage type 1 diabetes [119]. These are at the point of a positive autoantibody screen, at diagnosis of each stage, when monitoring tasks are performed, and annually for review and maintenance. Education is also critical during life transitions and milestones, and when care needs change.

Key education topics

Education and self-care behaviours for individuals at risk for or with early-stage diabetes (Table 1) can be derived from the overall framework of self-management skills for diabetes and related conditions. These are described in the ADCES7 self-care behaviours [125]. Those relevant for at-risk individuals or those with early-stage type 1 diabetes focus on understanding the implications of their single (at-risk) or multiple (early-stage type 1 diabetes) IAb+ status, and the benefits of regular monitoring. Symptom awareness and metabolic monitoring are important to reduce the risks of hospitalisation for DKA. If other family members have type 1 diabetes, HCPs should not assume pre-existing awareness and knowledge. The most-current education should always be mandated.

Educational topics of highest value for IAb+ individuals and family members

For an individual who has tested positive for one or more autoantibodies, a person-centred plan should be developed that is best suited to the IAb+ person and their individual situation. Their family members should be included as part of the programme of education. The topics that may have high value are likely to include the following: (1) understanding autoimmunity and the confirmation of single (at-risk) or multiple (early-stage type 1 diabetes) IAb+ status; (2) definition of at-risk or early-stage type 1 diabetes; (3) risk perception (accurate risk perception is linked with staying engaged in monitoring and with DKA prevention [126]); (4) risks and benefits of individual participation in research studies; (5) awareness of hyperglycaemia episodes for introducing insulin at the right time; (6) strategies for healthy coping; (7) symptom awareness and prevention of DKA; (8) glucose monitoring (SMBG, CGM), if clinically recommended; (9) healthy behaviours, including meal planning and physical activity; (10) risks and benefits of intervention therapies; (11) monitoring planning, with descriptions of laboratory tests and devices that may be used (Table 5); and (12) treatment options and introduction to insulin therapy.

Where should education be provided?

Education should be widely accessible via a variety of modalities, across multiple media platforms and settings, and should be crafted with the specific audience’s learning needs in mind. For education aimed at HCPs, a key requirement is for professional associations in all regions to be aligned with the educational programme and curriculum, preferably compatible with their educational platforms and with accreditation. For education aimed at people with pre-stage 3 type 1 diabetes, in-person options associated with clinical appointments or in-group sessions are important, and strong evidence supports DSMES delivery through virtual, telehealth, telephone, text messaging and web-based/mobile phone applications (apps) [127–131].

Who should provide education?

The competencies that must be addressed in education are outlined in Fig. 2. There is a need for diabetes professional associations to endorse the educational goals, educational tools and educational content, as described. Different groups of individuals, including HCPs, community members, and individuals in need of monitoring and their families (indicated in the pyramid sections in Fig. 2), should have the competencies described and participate as appropriate.

Fig. 2 The continuum of educational needs and competencies: what does one need to know? The image represents the anticipated skills that must be developed within the continuum of stakeholders in monitoring presymptomatic type 1 diabetes. The groups indicated within the pyramid sections should have the competencies described and participate as appropriate. The need is for unified, consistent, globally applicable language at all levels. T1D, type 1 diabetes. This figure is available as part of a downloadable slideset

7. Psychosocial support

What is the current landscape regarding psychosocial support for people with type 1 diabetes-related autoantibodies?

People who learn that they or a loved one have type 1 diabetes-related autoantibodies often experience significant stress [132]. This is in part because events that are unpredictable, uncontrollable and threatening may be highly stressful. People who have islet autoantibody positivity, particularly those who have multiple islet autoantibody positivity, will very likely develop type 1 diabetes in the future. However, disease progression is impossible to predict precisely and having IAb+ status does not mean imminent type 1 diabetes onset [133, 134]; stage 3 type 1 diabetes, with associated insulin administration and glycaemic monitoring, could be months or even years away [17].

When learning they have type 1 diabetes-related autoantibodies, individuals of all ages and their family members can experience a range of emotional and behavioural reactions [135, 136], including shock, grief, guilt, anger, depression and anxiety. If time passes with no diagnosis of stage 3 type 1 diabetes, cognitions about type 1 diabetes may change and individuals may become convinced they will never get the disease or have reduced risk, despite evidence to the contrary [137]. Parents often engage in behaviours in attempts to prevent type 1 diabetes when faced with the news that their child is at increased risk, even when not provided with recommendations to do so, though more-recent data have shown that lower physical activity and meal plans with a higher glycaemic index are associated with faster progression to type 1 diabetes [138–140]. Meal-planning changes are most commonly reported, with extra monitoring at home (including blood glucose checking) being particularly common in families with someone who already has type 1 diabetes [141, 142].

Research has documented the psychosocial impact of newborn screening [143], as well as genetic and islet autoantibody screening for type 1 diabetes [132, 136]. Failure to understand the screening and risk information presented is common. For example, more than a third of participating mothers and over half of participating fathers in the TEDDY study stated that their child was not at increased risk for type 1 diabetes, despite being clearly informed of their child’s increased genetic risk [137]. To date, no data are available on how children screened positive for islet autoantibodies perceive or react to their risk.

Emotional distress in response to a positive islet autoantibody screen is also common. Many parents of children in the TEDDY study experienced anxiety after learning that their child was at increased risk for developing type 1 diabetes, with mothers reporting higher anxiety than fathers [132]. Although anxiety decreased across time for parents of IAb+ children who never developed additional autoantibodies, anxiety remained elevated in many parents of children with multiple autoantibodies for years after the child’s first IAb+ test result. Mothers who experienced negative interpersonal life events and postpartum depression, but who were accurate about their child’s type 1 diabetes risk, were particularly vulnerable to heighted anxiety [144]. In the Autoimmunity Screening for Kids (ASK) study, which conducted islet autoantibody screening in the general population, 74.4% of parents reported significant levels of anxiety about their child’s type 1 diabetes risk at the first follow-up visit; parents with lower educational attainment were more likely to exhibit higher levels of anxiety [145].

Around 40% of mothers and 20% of fathers in the Fr1da study reported clinically elevated symptoms of depression after learning that their child was at increased risk for type 1 diabetes as compared with around 18% of mothers and fathers of children who were IAb− [24]. Depressive symptoms declined across 1 year, with scores in mothers of IAb+ children remaining slightly elevated as compared with mothers of IAb− children; scores in fathers did not remain elevated.

Although both the ADA and ISPAD have published recommendations about the psychosocial care of individuals with stage 3 type 1 diabetes [146–148], these are limited to general principles for care of those with early-stage type 1 diabetes [149]. Thus, there is an urgent need to provide guidance on psychosocial support for individuals with type 1 diabetes-related autoantibodies and their families.

We recognise regional differences in healthcare resources may limit mental-health resources for care of people with diabetes. In most areas, there are insufficient mental and behavioural health professionals with expertise in the psychosocial aspects of type 1 diabetes who can provide the care recommended by the ADA and ISPAD [146–148].

What is the purpose of psychosocial support?

The overall goal of providing psychosocial support for individuals identified as having early-stage type 1 diabetes and their families is to assist them in successfully managing the psychosocial impacts associated with this life-changing news. To accomplish this goal, emotional, cognitive and behavioural functioning need to be assessed and addressed, not only in individuals with type 1 diabetes-related autoantibodies but in their family members as well, when appropriate.

What type of support should be provided?

The essential first step is to ask the individual who is at risk for type 1 diabetes and/or their caregivers and family members about their reactions upon receiving the news that they have type 1 diabetes-related autoantibodies. However, asking once is not enough as adjustment to autoantibody status may change over time [132]. Enquiring about how individuals are coping with the news and their current needs should be conducted at every monitoring visit. Examples of questions to include in the conversation include:How do you feel about this news?

Others have said this news brings feelings of sadness or worry, what are your feelings?

What is your understanding about having multiple autoantibodies?

What type of things are you doing to try to prevent type 1 diabetes?

What are your thoughts about talking with a counsellor about your feelings from this news?

Providers can also assess global symptoms of anxiety and depression using age-appropriate standardised and validated questionnaires, such as the Patient Health Questionnaire-9 (PHQ-9) for depression [150] or the Hamilton Anxiety Scale [151]. However, global measures of anxiety and depression may not be sensitive to the emotional impact specifically associated with learning that one—or a loved one—has type 1 diabetes autoantibodies. In such cases, measures that assess emotional reactions to the IAb+ status, such as the ‘State’ component of the State-Trait Anxiety Inventory [152] may be more appropriate. At a minimum, HCPs should have conversations with individuals about their reactions to IAb+ results rather than relying solely on global measures of psychosocial functioning. Assessments should occur at regular intervals, since reactions are likely to change over time. Additional measures for both depression and anxiety in diabetes are provided in the ADA Psychosocial Care for People With Diabetes Position Statement [147], along with a directory of mental-health providers (https://my.diabetes.org/health-directory [153]).

It is also important to consider developmental and family-specific factors when assessing psychosocial needs. For example, children and adolescents with type 1 diabetes autoantibodies may experience varied emotional, cognitive and behavioural impacts as they develop. This further emphasises the need for ongoing, regular assessment of psychosocial needs. Additionally, individuals with a family history of type 1 diabetes may react differently to learning about type 1 diabetes-related autoantibodies [141] compared with those who are unfamiliar with the disease; family context and prior experience with type 1 diabetes are important considerations when assessing psychosocial impact and the need for additional support.

Although increased anxiety and depression can occur in individuals with type 1 diabetes-related autoantibodies and their family members, this can be reduced by monitoring for the potential development of type 1 diabetes [120]. Providing individuals with regular monitoring for type 1 diabetes, depending on stage, as outlined in earlier sections of this statement, can help individuals manage some of the unpredictability of type 1 diabetes development [120, 132].

Based on the extant literature, diabetes-focused organisations, such as the ADA and ISPAD, have provided recommendations on the importance of individuals with diagnosed type 1 diabetes receiving psychosocial care [146–148] that is preferably integrated into routine diabetes visits and delivered by providers with diabetes-specific training [154]. While the same level of evidence does not yet exist in those individuals with type 1 diabetes-related autoantibodies, the well-documented emotional, cognitive and behavioural impacts of autoantibody status certainly suggest that a similar standard for psychosocial care should be available for all individuals who are at risk for developing type 1 diabetes and their families. For individuals with early-stage type 1 diabetes and their family members, there are well-developed models of managing psychosocial reactions to risk status, including age-specific education and assigned contact people to answer questions, who can also serve as role models [9, 145].

Ideally, psychosocial care should be integrated with routine monitoring visits and delivered by HCPs using a collaborative, person-centred, culturally informed approach. When available, refer to mental and behavioural health professionals with expertise in type 1 diabetes for additional assessment and treatment. For individuals residing in the USA, the ADA publishes the Mental Health Provider Directory, which lists providers with expertise in diabetes [153].

8. Unmet needs for further research

This consensus document for monitoring individuals with single (at-risk) and multiple (early-stage type 1 diabetes) islet autoantibody positivity covers key principles based on existing evidence and agreed expert opinion. It also highlights the significant unmet need for further research on early-stage type 1 diabetes to further increase the rigour for future guidance and recommendations, and drive the evolution of clinical care for people who have tested positive for islet autoantibodies. The key principles in this consensus document will be subject to updating once additional evidence becomes available, as indicated in Table 6.

Supplementary Information

Below is the link to the electronic supplementary material.ESM Table (PDF 123 KB)

Slideset of figures (PPTX 277 KB)

Abbreviations

ADCES Association of Diabetes Care & Education Specialists

CGM Continuous glucose monitoring

DCES Diabetes care and education specialists

DKA Diabetic ketoacidosis

DSMES Diabetes self-management education and support

HCP Healthcare professional

IAb− Islet autoantibody negative

IAb+ Islet autoantibody positive

IASP Islet Autoantibody Standardisation Program

ISPAD International Society for Pediatric and Adolescent Diabetes

SMBG Self-monitored blood glucose

TEDDY The Environmental Determinants of Diabetes in the Young

Acknowledgements

The author group wish to thank JDRF for organising the initial expert conference and for providing funding to Robert Brines, Bite Medical Consulting (Cambridge, UK), who supported the author group by collating and compiling author feedback and revisions during the manuscript drafting process. The authors acknowledge the review and endorsement of the following organisations: Advanced Technologies & Treatments for Diabetes (ATTD); the American Association of Clinical Endocrinology (AACE); the American College of Diabetology (ACD); the American Diabetes Association (ADA); the Association of Diabetes Care & Education Specialists (ADCES); the Association for the Endocrine Society; the Australian Diabetes Society (ADS); DiaUnion; the European Association for the Study of Diabetes (EASD); the International Society for Paediatric and Adolescent Diabetes (ISPAD); and JDRF International. Parts of this work were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes Conference, Florence, Italy, 6–9 March 2024, and at the ADA 84th Scientific Sessions, Orlando, FL, USA, 21–24 June 2024.

Authors’ relationships and activities

MP has received honoraria for participation on advisory boards for AstraZeneca, Eli Lilly, MannKind Corp., Medtronic Diabetes, Pfizer, Sanofi, Dompé, LifeScan, Novo Nordisk, Insulet, Provention Bio, Merck, Ascensia Diabetes Care, Bayer, Embecta and Tandem Diabetes Care, and as a speaker for Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi and Ascensia Diabetes Care. MP owns stocks of DreaMed Diabetes and NG Solutions and his institution has received research grant support from Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi, DreaMed Diabetes, NG Solutions, Dompé, Lumos, GWave, OPKO, Provention Bio and AstraZeneca, travel expenses from Medtronic Diabetes and Sanofi, and consulting fees from Qulab Medical and Provention Bio. TB served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Medtronic, Abbott and Indigo Diabetes. TB received honoraria for participating on the speaker’s bureau for Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Dexcom, Adventis, AstraZeneca and Roche. TB’s institution has received research grant support and travel expenses from Abbott, Medtronic, Novo Nordisk, Sanofi, Novartis, Sandoz and Zealand Pharma. REJB has received consulting fees from Provention Bio. HMC has received research grant support from IQVIA, JDRF, Chief Scientist Office, Diabetes UK and the UK Medical Research Council (UKRI). HMC has received honorarium from Novo Nordisk and owns shares in Roche Pharmaceuticals and Bayer AG. TD has received honoraria and speaker honoraria and consulting fees and his former institution has received research support from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Provention Bio, Sanofi and Vertex Pharmaceuticals. He is a shareholder in DreamMed. Ltd. KD has received honorarium for participation on advisory boards for Medtronic and Novo Nordisk, and speaker fees from Abbott, Eli Lilly, Novo Nordisk, Medtronic and Pfizer. OE has received research support from MannKind Corp., Medtronic Diabetes, Abbott, Dexcom, Eli Lilly Pharmaceuticals, Janssen Pharmaceuticals and Vertex Pharmaceuticals. OE has also participated on advisory boards for Medtronic and Sanofi. OE has received consultation and speaker fees from Medtronic Diabetes, Sanofi and Vertex Pharmaceuticals. All financial support from industry for OE has been through his organisation, T1D Exchange. RAG has received honorarium from Lark, Sweetch, StartUp Health, Vida and Valendo. CJG’s institution received payment from Sanofi as a clinical trial centre. KJG has received sponsored travel from JDRF. WH received grant/consultancy fees from Sanofi/Provention Bio. MJH has received grants or consultancy fees from Sanofi, MannKind Corp. and SAB Biotherapeutics and is a stock options holder of SAB Biotherapeutics. RIGH has received honoraria for speaking from EASD, Eli Lilly, ENCORE, Liberum, Novo Nordisk, Rovi and Boehringer Ingelheim. RIGH has received conference funding from Novo Nordisk and Eli Lilly. OK has received honoraria and lecture fees from Sanofi, Dexcom and Medtronic. RWL has received a consultancy fee from Cigna Insurance. DMM has received research support from the National Institutes of Health, JDRF, National Science Foundation and the Leona M. and Harry B. Helmsley Charitable Trust, and his institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem Diabetes Care and Roche. CM serves or has served on advisory panels for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion and Vertex Pharmaceuticals. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics; CM serves or has served on speakers’ bureaus for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of EASD. All external support of EASD is to be found on www.easd.org. HKO’D received compensation from Sanofi for attending their advisory board and for speaking at ADA 84th Scientific Sessions. RP-B has received payment or honoraria from Bayer, Lexicon Pharma, Novo Nordisk, Averitas Pharma, Nevro, Roche and Medtronic. MJR has received honoraria and grants from Sanofi. KMS has received consultancy fees, grants or honoraria from Provention Bio and Sanofi. EKS has received consulting fees from Sanofi and DRI Healthcare and has received payment for lectures from Health Matters CME, Medscape, Med Learning Group LLC and the ADA. JSS has been a scientific advisory board member for 4Immune, ActoBiotics, Avotres and Quell Therapeutics. JSS has been a data safety board member for Imcyse and Provention Bio and is a member of the board of directors for SAB Therapeutics. JSS has been an advisor or consultant for ImmunoMolecular Therapeutics, Novo Nordisk, Remedy Plan Inc, SAB Therapeutics and Sanofi. JSS has shares in or is an option holder for 4Immune, Avotres, ImmunoMolecular Therapeutics, Remedy Plan Inc and SAB Therapeutics. CS has received research funding from Cour Pharmaceuticals and consultancy fees from Sanofi and GentiBio. LAD has received research support to their institution from Dompé, Lilly, MannKind Corp., Medtronic, Provention/Sanofi, and Zealand and consulting fees from Vertex Pharmaceuticals and Abata. LAD has a patent pending for use of difluoromethylornithine (DFMO). All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement

All listed authors were responsible for drafting the consensus guidance article and reviewing it critically for important intellectual content. All authors approved the final draft version of the manuscript submitted for publication.

This consensus report was endorsed by the European Society for the Study of Diabetes (EASD), American Diabetes Association (ADA), American Association of Clinical Endocrinology (AACE), American College of Diabetology (ACD), Association of Diabetes Care & Education Specialists (ADCES), Australian Diabetes Society (ADS), the International Society for Pediatric and Adolescent Diabetes (ISPAD), Advanced Technologies & Treatments for Diabetes (ATTD), DiaUnion, the Endocrine Society and JDRF International.

This article is being simultaneously published in Diabetes Care (10.2337/dci24-0042) and Diabetologia (10.1007/s00125-024-06205-5) by the ADA and the EASD.

A consensus report of a particular topic contains a comprehensive examination and is authored by an expert panel and represents the panel’s collective analysis, evaluation and opinion. Consensus reports are reviewed for EASD by its Committee for Clinical Affairs (CCA). The CCA may, at their discretion, enlist further external expert reviewers.

The original online version of this article was revised: Unfortunately, the affiliation for Linda A. DiMeglio was incorrect in this paper. The original article has been corrected.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

9/4/2024

A Correction to this paper has been published: 10.1007/s00125-024-06266-6
==== Refs
References

1. Gorsuch AN, Spencer KM, Lister J et al (1981) Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 2(8260–61):1363–5. 10.1016/s0140-6736(81)92795-1
2. Riley WJ, Atkinson MA, Schatz DA, Maclaren NK (1990) Comparison of islet autoantibodies in ‘pre-diabetes’ and recommendations for screening. J Autoimmun 3:47–51. 10.1016/S0896-8411(09)90009-9
3. Hirsch JS FDA approves teplizumab: a milestone in type 1 diabetes Lancet Diabetes Endocrinol 2023 11 1 18 10.1016/S2213-8587(22)00351-5 36436528
Hirsch JS (2023) FDA approves teplizumab: a milestone in type 1 diabetes. Lancet Diabetes Endocrinol 11(1):18. 10.1016/S2213-8587(22)00351-536436528
4. American Diabetes Association Professional Practice Committee 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes—2024 Diabetes Care 2024 47 Supplement_1 S43 S51 10.2337/dc24-S003 38078581
American Diabetes Association Professional Practice Committee (2024) 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes—2024. Diabetes Care 47(Supplement_1):S43–S51. 10.2337/dc24-S00338078581
5. TEDDY Study Group The Environmental Determinants of Diabetes in the Young (TEDDY) study Ann N Y Acad Sci 2008 1150 1 13 10.1196/annals.1447.062
TEDDY Study Group (2008) The Environmental Determinants of Diabetes in the Young (TEDDY) study. Ann N Y Acad Sci 1150:1–13. 10.1196/annals.1447.062
6. Frohnert BI Ide L Dong F Late-onset islet autoimmunity in childhood: the Diabetes Autoimmunity Study in the Young (DAISY) Diabetologia 2017 60 6 998 1006 10.1007/s00125-017-4256-9 28314946
Frohnert BI, Ide L, Dong F et al (2017) Late-onset islet autoimmunity in childhood: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 60(6):998–1006. 10.1007/s00125-017-4256-928314946
7. McQueen RB, Geno Rasmussen C, Waugh K et al (2020) Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care 43(7):1496–503. 10.2337/dc19-2003
8. Hamman RF Bell RA Dabelea D The SEARCH for Diabetes in Youth study: rationale, findings, and future directions Diabetes Care 2014 37 12 3336 44 10.2337/dc14-0574 25414389
Hamman RF, Bell RA, Dabelea D et al (2014) The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care 37(12):3336–44. 10.2337/dc14-057425414389
9. Raab J Haupt F Scholz M Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study BMJ Open 2016 6 5 e011144 10.1136/bmjopen-2016-011144 27194320
Raab J, Haupt F, Scholz M et al (2016) Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 6(5):e011144. 10.1136/bmjopen-2016-01114427194320
10. Bingley PJ Wherrett DK Shultz A Rafkin LE Atkinson MA Greenbaum CJ Type 1 diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes Diabetes Care 2018 41 4 653 61 10.2337/dc17-0806 29559451
Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ (2018) Type 1 diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes. Diabetes Care 41(4):653–61. 10.2337/dc17-080629559451
11. Lamichhane S Ahonen L Dyrlund TS Dynamics of plasma lipidome in progression to islet autoimmunity and type 1 diabetes – Type 1 Diabetes Prediction and Prevention Study (DIPP) Sci Rep 2018 8 1 10635 10.1038/s41598-018-28907-8 30006587
Lamichhane S, Ahonen L, Dyrlund TS et al (2018) Dynamics of plasma lipidome in progression to islet autoimmunity and type 1 diabetes – Type 1 Diabetes Prediction and Prevention Study (DIPP). Sci Rep 8(1):10635. 10.1038/s41598-018-28907-830006587
12. Butty V Campbell C Mathis D Benoist C DPT-1 Study Group Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the Diabetes Prevention Trial-Type 1 (DPT-1) Diabetes 2008 57 9 2348 59 10.2337/db07-1736 18556337
Butty V, Campbell C, Mathis D, Benoist C, DPT-1 Study Group (2008) Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 57(9):2348–59. 10.2337/db07-173618556337
13. European Nicotinamide Diabetes Intervention Trial Group Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT) Diabetologia 2003 46 3 339 46 10.1007/s00125-003-1033-8 12687331
European Nicotinamide Diabetes Intervention Trial Group (2003) Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 46(3):339–46. 10.1007/s00125-003-1033-812687331
14. Dunger DB Bruggraber SFA Mander AP INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes Trials 2022 23 1 414 10.1186/s13063-022-06259-z 35585600
Dunger DB, Bruggraber SFA, Mander AP et al (2022) INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes. Trials 23(1):414. 10.1186/s13063-022-06259-z35585600
15. Ziegler AG Hummel M Schenker M Bonifacio E Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study Diabetes 1999 48 3 460 8 10.2337/diabetes.48.3.460 10078544
Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48(3):460–8. 10.2337/diabetes.48.3.46010078544
16. Besser REJ Bell KJ Couper JJ ISPAD clinical practice consensus guidelines 2022: stages of type 1 diabetes in children and adolescents Pediatr Diabetes 2022 23 8 1175 87 10.1111/pedi.13410 36177823
Besser REJ, Bell KJ, Couper JJ et al (2022) ISPAD clinical practice consensus guidelines 2022: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 23(8):1175–87. 10.1111/pedi.1341036177823
17. Insel RA Dunne JL Atkinson MA Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association Diabetes Care 2015 38 10 1964 74 10.2337/dc15-1419 26404926
Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10):1964–74. 10.2337/dc15-141926404926
18. ElSayed NA Aleppo G Aroda VR 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023 Diabetes Care 2023 46 Supplement_1 S19 S40 10.2337/dc23-S002 36507649
ElSayed NA, Aleppo G, Aroda VR et al (2023) 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes Care 46(Supplement_1):S19–S40. 10.2337/dc23-S00236507649
19. Blonde L Umpierrez GE Reddy SS American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update Endocr Pract 2022 28 10 923 1049 10.1016/j.eprac.2022.08.002 35963508
Blonde L, Umpierrez GE, Reddy SS et al (2022) American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract 28(10):923–1049. 10.1016/j.eprac.2022.08.00235963508
20. Insel RA, Dunne JL, Ziegler AG (2015) General population screening for type 1 diabetes: has its time come? Curr Opin Endocrinol Diabetes Obes 22(4):270–6. 10.1097/MED.0000000000000173
21. Simmons KMW Frohnert BI O’Donnell HK Historical insights and current perspectives on the diagnosis and management of presymptomatic type 1 diabetes Diabetes Technol Ther 2023 25 11 790 9 10.1089/dia.2023.0276 37695674
Simmons KMW, Frohnert BI, O’Donnell HK et al (2023) Historical insights and current perspectives on the diagnosis and management of presymptomatic type 1 diabetes. Diabetes Technol Ther 25(11):790–9. 10.1089/dia.2023.027637695674
22. Herold KC Bundy BN Long SA An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes N Engl J Med 2019 381 7 603 13 10.1056/NEJMoa1902226 31180194
Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603–13. 10.1056/NEJMoa190222631180194
23. Besser REJ Ng SM Gregory JW Dayan CM Randell T Barrett T General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child 2022 107 9 790 5 10.1136/archdischild-2021-321864 34740879
Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T (2022) General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child 107(9):790–5. 10.1136/archdischild-2021-32186434740879
24. Ziegler AG Kick K Bonifacio E Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany JAMA 2020 323 4 339 51 10.1001/jama.2019.21565 31990315
Ziegler AG, Kick K, Bonifacio E et al (2020) Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 323(4):339–51. 10.1001/jama.2019.2156531990315
25. American Diabetes Association Professional Practice Committee 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024 Diabetes Care 2024 47 Supplement_1 S20 S42 10.2337/dc24-S002 38078589
American Diabetes Association Professional Practice Committee (2024) 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024. Diabetes Care 47(Supplement_1):S20–S42. 10.2337/dc24-S00238078589
26. Elding Larsson H, Vehik K, Bell R et al (2011) Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 34(11):2347–52. 10.2337/dc11-1026
27. Lundgren M Sahlin Å Svensson C Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up Pediatr Diabetes 2014 15 7 494 501 10.1111/pedi.12151 24823816
Lundgren M, Sahlin Å, Svensson C et al (2014) Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up. Pediatr Diabetes 15(7):494–501. 10.1111/pedi.1215124823816
28. Wentworth JM Oakey H Craig ME Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand Pediatr Diabetes 2022 23 8 1594 601 10.1111/pedi.13422 36175392
Wentworth JM, Oakey H, Craig ME et al (2022) Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand. Pediatr Diabetes 23(8):1594–601. 10.1111/pedi.1342236175392
29. Hekkala AM Ilonen J Toppari J Knip M Veijola R Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children Pediatr Diabetes 2018 19 2 314 9 10.1111/pedi.12541 28544185
Hekkala AM, Ilonen J, Toppari J, Knip M, Veijola R (2018) Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes 19(2):314–9. 10.1111/pedi.1254128544185
30. Jacobsen LM Vehik K Veijola R Heterogeneity of DKA incidence and age-specific clinical characteristics in children diagnosed with type 1 diabetes in the TEDDY study Diabetes Care 2022 45 3 624 33 10.2337/dc21-0422 35043162
Jacobsen LM, Vehik K, Veijola R et al (2022) Heterogeneity of DKA incidence and age-specific clinical characteristics in children diagnosed with type 1 diabetes in the TEDDY study. Diabetes Care 45(3):624–33. 10.2337/dc21-042235043162
31. Barker JM Goehrig SH Barriga K Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-Up Diabetes Care 2004 27 6 1399 404 10.2337/diacare.27.6.1399 15161795
Barker JM, Goehrig SH, Barriga K et al (2004) Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-Up. Diabetes Care 27(6):1399–404. 10.2337/diacare.27.6.139915161795
32. Rewers A Dong F Slover RH Klingensmith GJ Rewers M Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998–2012 JAMA 2015 313 15 1570 2 10.1001/jama.2015.1414 25898057
Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M (2015) Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998–2012. JAMA 313(15):1570–2. 10.1001/jama.2015.141425898057
33. Hummel S Carl J Friedl N Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation Diabetologia 2023 66 9 1633 42 10.1007/s00125-023-05953-0 37329450
Hummel S, Carl J, Friedl N et al (2023) Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia 66(9):1633–42. 10.1007/s00125-023-05953-037329450
34. Winkler C, Schober E, Ziegler A-G, Holl RW (2012) Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 13(4):308–13. 10.1111/j.1399-5448.2011.00829.x
35. Triolo TM Chase HP Barker JM DPT-1 Study Group Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset Diabetes Care 2009 32 5 769 73 10.2337/dc08-1872 19407074
Triolo TM, Chase HP, Barker JM, DPT-1 Study Group (2009) Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care 32(5):769–73. 10.2337/dc08-187219407074
36. Alonso GT Coakley A Pyle L Manseau K Thomas S Rewers A Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017 Diabetes Care 2020 43 1 117 21 10.2337/dc19-0428 31601639
Alonso GT, Coakley A, Pyle L, Manseau K, Thomas S, Rewers A (2020) Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017. Diabetes Care 43(1):117–21. 10.2337/dc19-042831601639
37. Praveen PA Hockett CW Ong TC Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries Pediatr Diabetes 2021 22 1 40 6 10.1111/pedi.12979 31943641
Praveen PA, Hockett CW, Ong TC et al (2021) Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes 22(1):40–6. 10.1111/pedi.1297931943641
38. Wersäll JH, Adolfsson P, Forsander G, Ricksten S-E, Hanas R (2021) Delayed referral is common even when new‐onset diabetes is suspected in children. A Swedish prospective observational study of diabetic ketoacidosis at onset of Type 1 diabetes. Pediatr Diabetes 22(6):900–8. 10.1111/pedi.13229
39. Birkebaek NH Kamrath C Grimsmann JM Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries Lancet Diabetes Endocrinol 2022 10 11 786 94 10.1016/S2213-8587(22)00246-7 36202118
Birkebaek NH, Kamrath C, Grimsmann JM et al (2022) Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol 10(11):786–94. 10.1016/S2213-8587(22)00246-736202118
40. Saydah SH Shrestha SS Zhang P Zhou X Imperatore G Medical costs among youth younger than 20 years of age with and without diabetic ketoacidosis at the time of diabetes diagnosis Diabetes Care 2019 42 12 2256 61 10.2337/dc19-1041 31575641
Saydah SH, Shrestha SS, Zhang P, Zhou X, Imperatore G (2019) Medical costs among youth younger than 20 years of age with and without diabetic ketoacidosis at the time of diabetes diagnosis. Diabetes Care 42(12):2256–61. 10.2337/dc19-104131575641
41. Chang DW Shapiro MF Association between intensive care unit utilization during hospitalization and costs, use of invasive procedures, and mortality JAMA Intern Med 2016 176 10 1492 9 10.1001/jamainternmed.2016.4298 27532500
Chang DW, Shapiro MF (2016) Association between intensive care unit utilization during hospitalization and costs, use of invasive procedures, and mortality. JAMA Intern Med 176(10):1492–9. 10.1001/jamainternmed.2016.429827532500
42. Patel A Singh D Bhatt P Thakkar B Akingbola OA Srivastav SK Incidence, trends, and outcomes of cerebral edema among children with diabetic ketoacidosis in the United States Clin Pediatr 2016 55 10 943 51 10.1177/0009922815617975
Patel A, Singh D, Bhatt P, Thakkar B, Akingbola OA, Srivastav SK (2016) Incidence, trends, and outcomes of cerebral edema among children with diabetic ketoacidosis in the United States. Clin Pediatr 55(10):943–51. 10.1177/0009922815617975
43. Duca LM Reboussin BA Pihoker C Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study Pediatr Diabetes 2019 20 2 172 9 10.1111/pedi.12809 30556249
Duca LM, Reboussin BA, Pihoker C et al (2019) Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study. Pediatr Diabetes 20(2):172–9. 10.1111/pedi.1280930556249
44. Clapin HF Earnest A Colman PG Diabetic ketoacidosis at onset of type 1 diabetes and long-term HbA1c in 7,961 children and young adults in the Australasian Diabetes Data Network Diabetes Care 2022 45 12 2918 25 10.2337/dc22-0853 36749868
Clapin HF, Earnest A, Colman PG et al (2022) Diabetic ketoacidosis at onset of type 1 diabetes and long-term HbA1c in 7,961 children and young adults in the Australasian Diabetes Data Network. Diabetes Care 45(12):2918–25. 10.2337/dc22-085336749868
45. Kelly L Tuthill A Does diabetic ketoacidosis at diagnosis of type 1 diabetes mellitus predict poorer long-term glycemic control Ir J Med Sci 2023 192 4 1703 9 10.1007/s11845-023-03345-2 37010775
Kelly L, Tuthill A (2023) Does diabetic ketoacidosis at diagnosis of type 1 diabetes mellitus predict poorer long-term glycemic control. Ir J Med Sci 192(4):1703–9. 10.1007/s11845-023-03345-237010775
46. Giannakopoulos A Chrysanthakopoulou N Efthymiadou A Chrysis D Diabetic ketosis vs ketoacidosis as initial presentation of pediatric type 1 diabetes mellitus. Associated features and rate of progression during the first two years after diagnosis J Diabetes Complications 2024 38 1 108667 10.1016/j.jdiacomp.2023.108667 38150983
Giannakopoulos A, Chrysanthakopoulou N, Efthymiadou A, Chrysis D (2024) Diabetic ketosis vs ketoacidosis as initial presentation of pediatric type 1 diabetes mellitus. Associated features and rate of progression during the first two years after diagnosis. J Diabetes Complications 38(1):108667. 10.1016/j.jdiacomp.2023.10866738150983
47. Karges B Prinz N Placzek K A comparison of familial and sporadic type 1 diabetes among young patients Diabetes Care 2021 44 5 1116 24 10.2337/dc20-1829 33824143
Karges B, Prinz N, Placzek K et al (2021) A comparison of familial and sporadic type 1 diabetes among young patients. Diabetes Care 44(5):1116–24. 10.2337/dc20-182933824143
48. Bonifacio E Achenbach P Birth and coming of age of islet autoantibodies Clin Exp Immunol 2019 198 3 294 305 10.1111/cei.13360 31397889
Bonifacio E, Achenbach P (2019) Birth and coming of age of islet autoantibodies. Clin Exp Immunol 198(3):294–305. 10.1111/cei.1336031397889
49. Vehik K Bonifacio E Lernmark Å Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study Diabetes Care 2020 43 9 2066 73 10.2337/dc19-2547 32641373
Vehik K, Bonifacio E, Lernmark Å et al (2020) Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study. Diabetes Care 43(9):2066–73. 10.2337/dc19-254732641373
50. Marzinotto I Pittman DL Williams AJK Islet autoantibody standardization program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops Diabetologia 2023 66 5 897 912 10.1007/s00125-023-05877-9 36759347
Marzinotto I, Pittman DL, Williams AJK et al (2023) Islet autoantibody standardization program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops. Diabetologia 66(5):897–912. 10.1007/s00125-023-05877-936759347
51. Ziegler AG Rewers M Simell O Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children JAMA 2013 309 23 2473 9 10.1001/jama.2013.6285 23780460
Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473–923780460
52. Frohnert BI Ghalwash M Li Y Refining the definition of stage 1 type 1 diabetes: an ontology-driven analysis of the heterogeneity of multiple islet autoimmunity Diabetes Care 2023 46 10 1753 61 10.2337/dc22-1960 36862942
Frohnert BI, Ghalwash M, Li Y et al (2023) Refining the definition of stage 1 type 1 diabetes: an ontology-driven analysis of the heterogeneity of multiple islet autoimmunity. Diabetes Care 46(10):1753–61. 10.2337/dc22-196036862942
53. Orban T Sosenko JM Cuthbertson D Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1 Diabetes Care 2009 32 12 2269 74 10.2337/dc09-0934 19741189
Orban T, Sosenko JM, Cuthbertson D et al (2009) Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32(12):2269–7419741189
54. Steck AK Vehik K Bonifacio E Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY) Diabetes Care 2015 38 5 808 13 10.2337/dc14-2426 25665818
Steck AK, Vehik K, Bonifacio E et al (2015) Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care 38(5):808–1325665818
55. Achenbach P Warncke K Reiter J Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics Diabetes 2004 53 2 384 92 10.2337/diabetes.53.2.384 14747289
Achenbach P, Warncke K, Reiter J et al (2004) Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 53(2):384–9214747289
56. Bosi E Boulware DC Becker DJ Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives J Clin Endocrinol Metab 2017 102 8 2881 6 10.1210/jc.2017-00569 28531305
Bosi E, Boulware DC, Becker DJ et al (2017) Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab 102(8):2881–6. 10.1210/jc.2017-0056928531305
57. Morran MP Casu A Arena VC Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of type 1 diabetes Endocrinology 2010 151 6 2528 37 10.1210/en.2009-1257 20382696
Morran MP, Casu A, Arena VC et al (2010) Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of type 1 diabetes. Endocrinology 151(6):2528–37. 10.1210/en.2009-125720382696
58. Ng K Stavropoulos H Anand V Islet autoantibody type-specific titer thresholds improve stratification of risk of progression to type 1 diabetes in children Diabetes Care 2022 45 1 160 8 10.2337/dc21-0878 34758977
Ng K, Stavropoulos H, Anand V et al (2022) Islet autoantibody type-specific titer thresholds improve stratification of risk of progression to type 1 diabetes in children. Diabetes Care 45(1):160–8. 10.2337/dc21-087834758977
59. Wherrett DK Chiang JL Delamater AM Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report Diabetes Care 2015 38 10 1975 85 10.2337/dc15-1429 26404927
Wherrett DK, Chiang JL, Delamater AM et al (2015) Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care 38(10):1975–85. 10.2337/dc15-142926404927
60. Muñoz C Floreen A Garey C Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives Clin Diabetes 2019 37 3 276 81 10.2337/cd18-0088 31371859
Muñoz C, Floreen A, Garey C et al (2019) Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives. Clin Diabetes 37(3):276–81. 10.2337/cd18-008831371859
61. Lawrence JM Slezak JM Quesenberry C Incidence and predictors of type 1 diabetes among younger adults aged 20–45 years: the Diabetes in Young Adults (DiYA) study Diabetes Res Clin Pract 2021 171 108624 10.1016/j.diabres.2020.108624 33338552
Lawrence JM, Slezak JM, Quesenberry C et al (2021) Incidence and predictors of type 1 diabetes among younger adults aged 20–45 years: the Diabetes in Young Adults (DiYA) study. Diabetes Res Clin Pract 171:108624. 10.1016/j.diabres.2020.10862433338552
62. Jones AG McDonald TJ Shields BM Hagopian W Hattersley AT Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes Diabetes Care 2021 44 6 1243 51 10.2337/dc20-2834 34016607
Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT (2021) Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes. Diabetes Care 44(6):1243–51. 10.2337/dc20-283434016607
63. Holt RIG DeVries JH Hess-Fischl A The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2021 64 12 2609 52 10.1007/s00125-021-05568-3 34590174
Holt RIG, DeVries JH, Hess-Fischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 64(12):2609–52. 10.1007/s00125-021-05568-334590174
64. Libman IM Pietropaolo M Arslanian SA LaPorte RE Becker DJ Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes Diabetes Care 2003 26 10 2871 5 10.2337/diacare.26.10.2871 14514594
Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26(10):2871–5. 10.2337/diacare.26.10.287114514594
65. Kavvoura FK Owen KR Maturity onset diabetes of the young: clinical characteristics, diagnosis and management Pediatr Endocrinol Rev 2012 10 2 234 42 23539835
Kavvoura FK, Owen KR (2012) Maturity onset diabetes of the young: clinical characteristics, diagnosis and management. Pediatr Endocrinol Rev 10(2):234–4223539835
66. Vehik K Boulware D Killian M Rising hemoglobin A1c in the nondiabetic range predicts progression of type 1 diabetes as well as oral glucose tolerance tests Diabetes Care 2022 45 10 2342 9 10.2337/dc22-0828 36150054
Vehik K, Boulware D, Killian M et al (2022) Rising hemoglobin A1c in the nondiabetic range predicts progression of type 1 diabetes as well as oral glucose tolerance tests. Diabetes Care 45(10):2342–9. 10.2337/dc22-082836150054
67. Helminen O Aspholm S Pokka T HbA1c predicts time to diagnosis of type 1 diabetes in children at risk Diabetes 2015 64 5 1719 27 10.2337/db14-0497 25524912
Helminen O, Aspholm S, Pokka T et al (2015) HbA1c predicts time to diagnosis of type 1 diabetes in children at risk. Diabetes 64(5):1719–27. 10.2337/db14-049725524912
68. Ismail HM Becker DJ Libman I Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals Diabetes Obes Metab 2020 22 6 997 1000 10.1111/dom.13982 32003110
Ismail HM, Becker DJ, Libman I et al (2020) Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals. Diabetes Obes Metab 22(6):997–1000. 10.1111/dom.1398232003110
69. Greenbaum CJ Anderson AM Dolan LM Preservation of β-cell function in autoantibody-positive youth with diabetes Diabetes Care 2009 32 10 1839 44 10.2337/dc08-2326 19587365
Greenbaum CJ, Anderson AM, Dolan LM et al (2009) Preservation of β-cell function in autoantibody-positive youth with diabetes. Diabetes Care 32(10):1839–44. 10.2337/dc08-232619587365
70. Hao W Gitelman S DiMeglio LA Boulware D Greenbaum CJ Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose Diabetes Care 2016 39 1664 70 10.2337/dc16-0360 27422577
Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ (2016) Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose. Diabetes Care 39:1664–70. 10.2337/dc16-036027422577
71. Wilson DM Pietropaolo SL Acevedo-Calado M CGM metrics identify dysglycemic states in participants from the TrialNet Pathway to Prevention study Diabetes Care 2023 46 3 526 34 10.2337/dc22-1297 36730530
Wilson DM, Pietropaolo SL, Acevedo-Calado M et al (2023) CGM metrics identify dysglycemic states in participants from the TrialNet Pathway to Prevention study. Diabetes Care 46(3):526–34. 10.2337/dc22-129736730530
72. Steck AK, Dong F, Geno Rasmussen C et al (2022) CGM metrics predict imminent progression to type 1 diabetes: Autoimmunity Screening for Kids (ASK) study. Diabetes Care 45(2):365–71. 10.2337/dc21-0602
73. Kontola H Alanko I Koskenniemi JJ Exploring minimally invasive approach to define stages of type 1 diabetes remotely Diabetes Technol Ther 2022 24 9 655 65 10.1089/dia.2021.0554 35653748
Kontola H, Alanko I, Koskenniemi JJ et al (2022) Exploring minimally invasive approach to define stages of type 1 diabetes remotely. Diabetes Technol Ther 24(9):655–65. 10.1089/dia.2021.055435653748
74. Ylescupidez A Speake C Pietropaolo SL OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody–positive individuals J Clin Endocrinol Metab 2023 109 1 57 67 10.1210/clinem/dgad472 37572381
Ylescupidez A, Speake C, Pietropaolo SL et al (2023) OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody–positive individuals. J Clin Endocrinol Metab 109(1):57–67. 10.1210/clinem/dgad47237572381
75. ElSayed NA Aleppo G Aroda VR Introduction and methodology: standards of care in diabetes—2023 Diabetes Care 2023 46 Supplement_1 S1 S4 10.2337/dc23-Sint 36507647
ElSayed NA, Aleppo G, Aroda VR et al (2023) Introduction and methodology: standards of care in diabetes—2023. Diabetes Care 46(Supplement_1):S1–S4. 10.2337/dc23-Sint36507647
76. Driscoll KA Tamura R Johnson SB Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: the TEDDY study Pediatr Diabetes 2021 22 2 360 8 10.1111/pedi.13149 33179853
Driscoll KA, Tamura R, Johnson SB et al (2021) Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: the TEDDY study. Pediatr Diabetes 22(2):360–8. 10.1111/pedi.1314933179853
77. Steck AK Dong F Taki I Continuous glucose monitoring predicts progression to diabetes in autoantibody positive children J Clin Endocrinol Metab 2019 104 8 3337 44 10.1210/jc.2018-02196 30844073
Steck AK, Dong F, Taki I et al (2019) Continuous glucose monitoring predicts progression to diabetes in autoantibody positive children. J Clin Endocrinol Metab 104(8):3337–44. 10.1210/jc.2018-0219630844073
78. Montaser E Brown SA DeBoer MD Farhy LS Predicting the risk of developing type 1 diabetes using a one-week continuous glucose monitoring home test with classification enhanced by machine-learning: an exploratory study J Diabetes Sci Technol 2024 18 2 257 65 10.1177/19322968231209302 37946401
Montaser E, Brown SA, DeBoer MD, Farhy LS (2024) Predicting the risk of developing type 1 diabetes using a one-week continuous glucose monitoring home test with classification enhanced by machine-learning: an exploratory study. J Diabetes Sci Technol 18(2):257–65. 10.1177/1932296823120930237946401
79. Montaser E Breton MD Brown SA DeBoer MD Kovatchev B Farhy LS Predicting immunological risk for stage 1 and stage 2 diabetes using a 1-week CGM home test, nocturnal glucose increments, and standardized liquid mixed meal breakfasts, with classification enhanced by machine learning Diabetes Technol Ther 2023 25 9 631 42 10.1089/dia.2023.0064 37184602
Montaser E, Breton MD, Brown SA, DeBoer MD, Kovatchev B, Farhy LS (2023) Predicting immunological risk for stage 1 and stage 2 diabetes using a 1-week CGM home test, nocturnal glucose increments, and standardized liquid mixed meal breakfasts, with classification enhanced by machine learning. Diabetes Technol Ther 25(9):631–42. 10.1089/dia.2023.006437184602
80. O’Rourke C Ylescupidez A Bahnson HT Risk modeling to reduce monitoring of an autoantibody-positive population to prevent DKA at type 1 diabetes diagnosis J Clin Endocrinol Metab 2023 108 3 688 96 10.1210/clinem/dgac594 36227635
O’Rourke C, Ylescupidez A, Bahnson HT et al (2023) Risk modeling to reduce monitoring of an autoantibody-positive population to prevent DKA at type 1 diabetes diagnosis. J Clin Endocrinol Metab 108(3):688–96. 10.1210/clinem/dgac59436227635
81. Sims EK Geyer S Johnson SB Who is enrolling? The path to monitoring in type 1 diabetes TrialNet’s Pathway to Prevention Diabetes Care 2019 42 12 2228 36 10.2337/dc19-0593 31558546
Sims EK, Geyer S, Johnson SB et al (2019) Who is enrolling? The path to monitoring in type 1 diabetes TrialNet’s Pathway to Prevention. Diabetes Care 42(12):2228–36. 10.2337/dc19-059331558546
82. Kimpimäki T Kulmala P Savola K Natural history of β-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population J Clin Endocrinol Metab 2002 87 10 4572 9 10.1210/jc.2002-020018 12364437
Kimpimäki T, Kulmala P, Savola K et al (2002) Natural history of β-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 87(10):4572–9. 10.1210/jc.2002-02001812364437
83. Vehik K Lynch KF Schatz DA Reversion of β-cell autoimmunity changes risk of type 1 diabetes: TEDDY study Diabetes Care 2016 39 9 1535 42 10.2337/dc16-0181 27311490
Vehik K, Lynch KF, Schatz DA et al (2016) Reversion of β-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care 39(9):1535–42. 10.2337/dc16-018127311490
84. Krischer JP Liu X Lernmark Å Predictors of the initiation of islet autoimmunity and progression to multiple autoantibodies and clinical diabetes: the TEDDY study Diabetes Care 2022 45 10 2271 81 10.2337/dc21-2612 36150053
Krischer JP, Liu X, Lernmark Å et al (2022) Predictors of the initiation of islet autoimmunity and progression to multiple autoantibodies and clinical diabetes: the TEDDY study. Diabetes Care 45(10):2271–81. 10.2337/dc21-261236150053
85. Chmiel R Giannopoulou EZ Winkler C Achenbach P Ziegler AG Bonifacio E Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening Diabetologia 2015 58 2 411 3 10.1007/s00125-014-3443-1 25409656
Chmiel R, Giannopoulou EZ, Winkler C, Achenbach P, Ziegler AG, Bonifacio E (2015) Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia 58(2):411–3. 10.1007/s00125-014-3443-125409656
86. So M O’Rourke C Ylescupidez A Characterising the age-dependent effects of risk factors on type 1 diabetes progression Diabetologia 2022 65 4 684 94 10.1007/s00125-021-05647-5 35041021
So M, O’Rourke C, Ylescupidez A et al (2022) Characterising the age-dependent effects of risk factors on type 1 diabetes progression. Diabetologia 65(4):684–94. 10.1007/s00125-021-05647-535041021
87. Anand V Li Y Liu B Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S Diabetes Care 2021 44 10 2269 76 10.2337/dc20-1836 34162665
Anand V, Li Y, Liu B et al (2021) Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S. Diabetes Care 44(10):2269–76. 10.2337/dc20-183634162665
88. Bonifacio E Weiß A Winkler C An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood Diabetes Care 2021 44 10 2260 8 10.2337/dc20-2122 33627366
Bonifacio E, Weiß A, Winkler C et al (2021) An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care 44(10):2260–8. 10.2337/dc20-212233627366
89. Bonifacio E Predicting type 1 diabetes using biomarkers Diabetes Care 2015 38 6 989 96 10.2337/dc15-0101 25998291
Bonifacio E (2015) Predicting type 1 diabetes using biomarkers. Diabetes Care 38(6):989–96. 10.2337/dc15-010125998291
90. Bingley PJ Boulware DC Krischer JP Type 1 Diabetes TrialNet Study Group The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes Diabetologia 2016 59 3 542 9 10.1007/s00125-015-3830-2 26676824
Bingley PJ, Boulware DC, Krischer JP, Type 1 Diabetes TrialNet Study Group (2016) The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia 59(3):542–9. 10.1007/s00125-015-3830-226676824
91. Schneider J Gemulla G Kiess W Berner R Hommel A Presymptomatic type 1 diabetes and disease severity at onset Diabetologia 2023 66 12 2387 8 10.1007/s00125-023-05999-0 37750892
Schneider J, Gemulla G, Kiess W, Berner R, Hommel A (2023) Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia 66(12):2387–8. 10.1007/s00125-023-05999-037750892
92. Hummel S Friedl N Winkler C Ziegler AG Achenbach P Presymptomatic type 1 diabetes and disease severity at onset. Reply to Schneider J, Gemulla G, Kiess W et al [letter] Diabetologia 2023 66 12 2389 90 10.1007/s00125-023-06017-z 37723346
Hummel S, Friedl N, Winkler C, Ziegler AG, Achenbach P (2023) Presymptomatic type 1 diabetes and disease severity at onset. Reply to Schneider J, Gemulla G, Kiess W et al [letter]. Diabetologia 66(12):2389–90. 10.1007/s00125-023-06017-z37723346
93. Ghalwash M Dunne JL Lundgren M Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study Lancet Diabetes Endocrinol 2022 10 8 589 96 10.1016/S2213-8587(22)00141-3 35803296
Ghalwash M, Dunne JL, Lundgren M et al (2022) Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 10(8):589–96. 10.1016/S2213-8587(22)00141-335803296
94. Weiss A Zapardiel-Gonzalo J Voss F Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening Diabetologia 2022 65 12 2121 31 10.1007/s00125-022-05780-9 36028774
Weiss A, Zapardiel-Gonzalo J, Voss F et al (2022) Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia 65(12):2121–31. 10.1007/s00125-022-05780-936028774
95. So M O’Rourke C Bahnson HT Greenbaum CJ Speake C Autoantibody reversion: changing risk categories in multiple-autoantibody–positive individuals Diabetes Care 2020 43 4 913 7 10.2337/dc19-1731 32019856
So M, O’Rourke C, Bahnson HT, Greenbaum CJ, Speake C (2020) Autoantibody reversion: changing risk categories in multiple-autoantibody–positive individuals. Diabetes Care 43(4):913–7. 10.2337/dc19-173132019856
96. Helminen O Aspholm S Pokka T OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis Diabetologia 2015 58 8 1787 96 10.1007/s00125-015-3621-9 25985749
Helminen O, Aspholm S, Pokka T et al (2015) OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. Diabetologia 58(8):1787–96. 10.1007/s00125-015-3621-925985749
97. Herold KC Gitelman SE Gottlieb PA Knecht LA Raymond R Ramos EL Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function Diabetes Care 2023 46 10 1848 56 10.2337/dc23-0675 37607392
Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL (2023) Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function. Diabetes Care 46(10):1848–56. 10.2337/dc23-067537607392
98. Thunander M Petersson C Jonzon K Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden Diabetes Res Clin Pract 2008 82 2 247 55 10.1016/j.diabres.2008.07.022 18804305
Thunander M, Petersson C, Jonzon K et al (2008) Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 82(2):247–55. 10.1016/j.diabres.2008.07.02218804305
99. Rogers MAM Kim C Banerjee T Lee JM Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study BMC Med 2017 15 1 199 10.1186/s12916-017-0958-6 29115947
Rogers MAM, Kim C, Banerjee T, Lee JM (2017) Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med 15(1):199. 10.1186/s12916-017-0958-629115947
100. Weng J Zhou Z Guo L Incidence of type 1 diabetes in China, 2010–13: population based study BMJ 2018 360 j5295 10.1136/bmj.j5295 29298776
Weng J, Zhou Z, Guo L et al (2018) Incidence of type 1 diabetes in China, 2010–13: population based study. BMJ 360:j5295. 10.1136/bmj.j529529298776
101. Diaz-Valencia PA Bougnères P Valleron AJ Global epidemiology of type 1 diabetes in young adults and adults: a systematic review BMC Public Health 2015 15 255 10.1186/s12889-015-1591-y 25849566
Diaz-Valencia PA, Bougnères P, Valleron AJ (2015) Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 15:255. 10.1186/s12889-015-1591-y25849566
102. Thomas NJ Hill AV Dayan CM Age of diagnosis does not alter the presentation or progression of robustly defined adult-onset type 1 diabetes Diabetes Care 2023 46 6 1156 63 10.2337/dc22-2159 36802355
Thomas NJ, Hill AV, Dayan CM et al (2023) Age of diagnosis does not alter the presentation or progression of robustly defined adult-onset type 1 diabetes. Diabetes Care 46(6):1156–63. 10.2337/dc22-215936802355
103. Gregory GA Robinson TIG Linklater SE Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study Lancet Diabetes Endocrinol 2022 10 10 741 60 10.1016/S2213-8587(22)00218-2 36113507
Gregory GA, Robinson TIG, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 10(10):741–60. 10.1016/S2213-8587(22)00218-236113507
104. Hawa MI, Kolb H, Schloot N et al (2013) Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA-7. Diabetes Care 36(4):908–13. 10.2337/dc12-0931
105. Xiang Y Huang G Zhu Y Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide survey Diabetes Obes Metab 2019 21 4 893 902 10.1111/dom.13595 30471182
Xiang Y, Huang G, Zhu Y et al (2019) Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide survey. Diabetes Obes Metab 21(4):893–902. 10.1111/dom.1359530471182
106. Rolandsson O Hampe CS Sharp SJ Autoimmunity plays a role in the onset of diabetes after 40 years of age Diabetologia 2020 63 2 266 77 10.1007/s00125-019-05016-3 31713011
Rolandsson O, Hampe CS, Sharp SJ et al (2020) Autoimmunity plays a role in the onset of diabetes after 40 years of age. Diabetologia 63(2):266–77. 10.1007/s00125-019-05016-331713011
107. Yasui J Kawasaki E Tanaka S Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan PLoS One 2016 11 5 e0155643 10.1371/journal.pone.0155643 27177031
Yasui J, Kawasaki E, Tanaka S et al (2016) Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS One 11(5):e0155643. 10.1371/journal.pone.015564327177031
108. Hanna SJ Powell WE Long AE Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype Diabetologia 2020 63 6 1174 85 10.1007/s00125-020-05114-7 32157332
Hanna SJ, Powell WE, Long AE et al (2020) Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia 63(6):1174–85. 10.1007/s00125-020-05114-732157332
109. Brooks-Worrell B Hampe CS Hattery EG Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the GRADE study Diabetes 2022 71 6 1261 71 10.2337/db21-0590 35061024
Brooks-Worrell B, Hampe CS, Hattery EG et al (2022) Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the GRADE study. Diabetes 71(6):1261–71. 10.2337/db21-059035061024
110. Greenbaum CJ, Beam CA, Boulware D et al (2012) Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61(8):2066–73. 10.2337/db11-1538
111. American Diabetes Association Screening for type 2 diabetes Diabetes Care 2004 27 suppl_1 s11 s4 10.2337/diacare.27.2007.S11 14693922
American Diabetes Association (2004) Screening for type 2 diabetes. Diabetes Care 27(suppl_1):s11–s4. 10.2337/diacare.27.2007.S1114693922
112. US Preventive Services Task Force (2021) Prediabetes and type 2 diabetes: screening. Available from: www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes. Accessed: 3 May 2024
113. Iqbal S Jayyab AA Alrashdi AM Reverté-Villarroya S The predictive ability of C-peptide in distinguishing type 1 diabetes from type 2 diabetes: a systematic review and meta-analysis Endocr Pract 2023 29 5 379 87 10.1016/j.eprac.2023.01.004 36641115
Iqbal S, Jayyab AA, Alrashdi AM, Reverté-Villarroya S (2023) The predictive ability of C-peptide in distinguishing type 1 diabetes from type 2 diabetes: a systematic review and meta-analysis. Endocr Pract 29(5):379–87. 10.1016/j.eprac.2023.01.00436641115
114. Löbner K Knopff A Baumgarten A Predictors of postpartum diabetes in women with gestational diabetes mellitus Diabetes 2006 55 3 792 7 10.2337/diabetes.55.03.06.db05-0746 16505245
Löbner K, Knopff A, Baumgarten A et al (2006) Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 55(3):792–7. 10.2337/diabetes.55.03.06.db05-074616505245
115. Dirar AM Doupis J Gestational diabetes from A to Z World J Diabetes 2017 8 12 489 511 10.4239/wjd.v8.i12.489 29290922
Dirar AM, Doupis J (2017) Gestational diabetes from A to Z. World J Diabetes 8(12):489–511. 10.4239/wjd.v8.i12.48929290922
116. Murphy HR Howgate C O’Keefe J Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study Lancet Diabetes Endocrinol 2021 9 3 153 64 10.1016/S2213-8587(20)30406-X 33516295
Murphy HR, Howgate C, O’Keefe J et al (2021) Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study. Lancet Diabetes Endocrinol 9(3):153–64. 10.1016/S2213-8587(20)30406-X33516295
117. Evers IM de Valk HW Visser GHA Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands BMJ 2004 328 7445 915 10.1136/bmj.38043.583160.EE 15066886
Evers IM, de Valk HW, Visser GHA (2004) Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 328(7445):915. 10.1136/bmj.38043.583160.EE15066886
118. Simmons D Immanuel J Hague WM Treatment of gestational diabetes mellitus diagnosed early in pregnancy New Engl J Med 2023 388 23 2132 44 10.1056/NEJMoa2214956 37144983
Simmons D, Immanuel J, Hague WM et al (2023) Treatment of gestational diabetes mellitus diagnosed early in pregnancy. New Engl J Med 388(23):2132–44. 10.1056/NEJMoa221495637144983
119. Davis J Fischl AH Beck J 2022 National standards for diabetes self-management education and support Diabetes Care 2022 45 2 484 94 10.2337/dc21-2396 35050365
Davis J, Fischl AH, Beck J et al (2022) 2022 National standards for diabetes self-management education and support. Diabetes Care 45(2):484–94. 10.2337/dc21-239635050365
120. Smith LB Liu X Johnson SB Family adjustment to diabetes diagnosis in children: can participation in a study on type 1 diabetes genetic risk be helpful? Pediatr Diabetes 2018 19 5 1025 33 10.1111/pedi.12674 29577538
Smith LB, Liu X, Johnson SB et al (2018) Family adjustment to diabetes diagnosis in children: can participation in a study on type 1 diabetes genetic risk be helpful? Pediatr Diabetes 19(5):1025–33. 10.1111/pedi.1267429577538
121. Vanelli M Chiari G Ghizzoni L Costi G Giacalone T Chiarelli F Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices Diabetes Care 1999 22 1 7 9 10.2337/diacare.22.1.7 10333896
Vanelli M, Chiari G, Ghizzoni L, Costi G, Giacalone T, Chiarelli F (1999) Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices. Diabetes Care 22(1):7–9. 10.2337/diacare.22.1.710333896
122. Patwardhan R Gorton S Vangaveti VN Yates J Diabetic ketoacidosis incidence in children at first presentation of type 1 diabetes at an Australian regional hospital: the effect of health professional education Pediatr Diabetes 2018 19 5 993 9 10.1111/pedi.12666 29484782
Patwardhan R, Gorton S, Vangaveti VN, Yates J (2018) Diabetic ketoacidosis incidence in children at first presentation of type 1 diabetes at an Australian regional hospital: the effect of health professional education. Pediatr Diabetes 19(5):993–9. 10.1111/pedi.1266629484782
123. Fritsch M Schober E Rami-Merhar B Diabetic ketoacidosis at diagnosis in Austrian children: a population-based analysis, 1989–2011 J Pediatr 2013 163 5 1484 8.e1 10.1016/j.jpeds.2013.06.033 23953724
Fritsch M, Schober E, Rami-Merhar B et al (2013) Diabetic ketoacidosis at diagnosis in Austrian children: a population-based analysis, 1989–2011. J Pediatr 163(5):1484–8.e1. 10.1016/j.jpeds.2013.06.03323953724
124. Rabbone I Maltoni G Tinti D Diabetic ketoacidosis at the onset of disease during a national awareness campaign: a 2-year observational study in children aged 0–18 years Arch Dis Child 2020 105 4 363 6 10.1136/archdischild-2019-316903 31597646
Rabbone I, Maltoni G, Tinti D et al (2020) Diabetic ketoacidosis at the onset of disease during a national awareness campaign: a 2-year observational study in children aged 0–18 years. Arch Dis Child 105(4):363–6. 10.1136/archdischild-2019-31690331597646
125. Association of Diabetes Care and Education SpecialistsKolb L An effective model of diabetes care and education: the ADCES7 self-care behaviors Sci Diabetes Self Manag Care 2021 47 1 30 53 10.1177/0145721720978154 34078208
Association of Diabetes Care and Education Specialists, Kolb L (2021) An effective model of diabetes care and education: the ADCES7 self-care behaviors. Sci Diabetes Self Manag Care 47(1):30–53. 10.1177/014572172097815434078208
126. Baughcum AE Johnson SB Carmichael SK Lewin AB She JX Schatz DA Maternal efforts to prevent type 1 diabetes in at-risk children Diabetes Care 2005 28 4 916 21 10.2337/diacare.28.4.916 15793195
Baughcum AE, Johnson SB, Carmichael SK, Lewin AB, She JX, Schatz DA (2005) Maternal efforts to prevent type 1 diabetes in at-risk children. Diabetes Care 28(4):916–21. 10.2337/diacare.28.4.91615793195
127. Bakhach M Reid MW Pyatak EA Home telemedicine (CoYoT1 Clinic): a novel approach to improve psychosocial outcomes in young adults with diabetes Diabetes Educ 2019 45 4 420 30 10.1177/0145721719858080 31244396
Bakhach M, Reid MW, Pyatak EA et al (2019) Home telemedicine (CoYoT1 Clinic): a novel approach to improve psychosocial outcomes in young adults with diabetes. Diabetes Educ 45(4):420–30. 10.1177/014572171985808031244396
128. Fernandes BSM, Reis IA, Torres HdC (2016) Evaluation of the telephone intervention in the promotion of diabetes self-care: a randomized clinical trial. Rev Lat Am Enfermagem 24:e2719. 10.1590/1518-8345.0632.2719
129. von Storch K Graaf E Wunderlich M Rietz C Polidori MC Woopen C Telemedicine-assisted self-management program for type 2 diabetes patients Diabetes Technol Ther 2019 21 9 514 21 10.1089/dia.2019.0056 31287736
von Storch K, Graaf E, Wunderlich M, Rietz C, Polidori MC, Woopen C (2019) Telemedicine-assisted self-management program for type 2 diabetes patients. Diabetes Technol Ther 21(9):514–21. 10.1089/dia.2019.005631287736
130. Toma T Athanasiou T Harling L Darzi A Ashrafian H Online social networking services in the management of patients with diabetes mellitus: systematic review and meta-analysis of randomised controlled trials Diabetes Res Clin Pract 2014 106 2 200 11 10.1016/j.diabres.2014.06.008 25043399
Toma T, Athanasiou T, Harling L, Darzi A, Ashrafian H (2014) Online social networking services in the management of patients with diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 106(2):200–11. 10.1016/j.diabres.2014.06.00825043399
131. Saffari M Ghanizadeh G Koenig HG Health education via mobile text messaging for glycemic control in adults with type 2 diabetes: a systematic review and meta-analysis Prim Care Diabetes 2014 8 4 275 85 10.1016/j.pcd.2014.03.004 24793589
Saffari M, Ghanizadeh G, Koenig HG (2014) Health education via mobile text messaging for glycemic control in adults with type 2 diabetes: a systematic review and meta-analysis. Prim Care Diabetes 8(4):275–85. 10.1016/j.pcd.2014.03.00424793589
132. Johnson SB Lynch KF Roth R Schatz D TEDDY Study Group My child is islet autoantibody positive: impact on parental anxiety Diabetes Care 2017 40 9 1167 72 10.2337/dc17-0166 28663383
Johnson SB, Lynch KF, Roth R, Schatz D, TEDDY Study Group (2017) My child is islet autoantibody positive: impact on parental anxiety. Diabetes Care 40(9):1167–72. 10.2337/dc17-016628663383
133. Bonifacio E Beyerlein A Hippich M Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children PLoS Med 2018 15 4 e1002548 10.1371/journal.pmed.1002548 29614081
Bonifacio E, Beyerlein A, Hippich M et al (2018) Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children. PLoS Med 15(4):e1002548. 10.1371/journal.pmed.100254829614081
134. Sharp SA Rich SS Wood AR Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis Diabetes Care 2019 42 2 200 7 10.2337/dc18-1785 30655379
Sharp SA, Rich SS, Wood AR et al (2019) Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care 42(2):200–7. 10.2337/dc18-178530655379
135. Bennett Johnson S, Tercyak KP (1995) Psychological impact of islet cell antibody screening for IDDM on children, adults, and their family members. Diabetes Care 18(10):1370–2. 10.2337/diacare.18.10.1370
136. Johnson SB Psychological impact of screening and prediction in type 1 diabetes Curr Diab Rep 2011 11 5 454 9 10.1007/s11892-011-0208-9 21710195
Johnson SB (2011) Psychological impact of screening and prediction in type 1 diabetes. Curr Diab Rep 11(5):454–9. 10.1007/s11892-011-0208-921710195
137. Swartling U Lynch K Smith L Johnson SB TEDDY Study Group Parental estimation of their child’s increased type 1 diabetes risk during the first 2 years of participation in an international observational study J Empir Res Hum Res Ethics 2016 11 2 106 14 10.1177/1556264616648589 27241873
Swartling U, Lynch K, Smith L, Johnson SB, TEDDY Study Group (2016) Parental estimation of their child’s increased type 1 diabetes risk during the first 2 years of participation in an international observational study. J Empir Res Hum Res Ethics 11(2):106–14. 10.1177/155626461664858927241873
138. Liu X Johnson SB Lynch KF Physical activity and the development of islet autoimmunity and type 1 diabetes in 5- to 15-year-old children followed in the TEDDY study Diabetes Care 2023 46 7 1409 16 10.2337/dc23-0036 37141102
Liu X, Johnson SB, Lynch KF et al (2023) Physical activity and the development of islet autoimmunity and type 1 diabetes in 5- to 15-year-old children followed in the TEDDY study. Diabetes Care 46(7):1409–16. 10.2337/dc23-003637141102
139. Lamb MM Yin X Barriga K Dietary glycemic index, development of islet autoimmunity, and subsequent progression to type 1 diabetes in young children J Clin Endocrinol Metab 2008 93 10 3936 42 10.1210/jc.2008-0886 18682514
Lamb MM, Yin X, Barriga K et al (2008) Dietary glycemic index, development of islet autoimmunity, and subsequent progression to type 1 diabetes in young children. J Clin Endocrinol Metab 93(10):3936–42. 10.1210/jc.2008-088618682514
140. Lamb MM Frederiksen B Seifert JA Kroehl M Rewers M Norris JM Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young Diabetologia 2015 58 9 2027 34 10.1007/s00125-015-3657-x 26048237
Lamb MM, Frederiksen B, Seifert JA, Kroehl M, Rewers M, Norris JM (2015) Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young. Diabetologia 58(9):2027–34. 10.1007/s00125-015-3657-x26048237
141. Smith LB Lynch KF Driscoll KA Johnson SB TEDDY Study Group Parental monitoring for type 1 diabetes in genetically at-risk young children: the TEDDY study Pediatr Diabetes 2021 22 5 717 28 10.1111/pedi.13173 33704891
Smith LB, Lynch KF, Driscoll KA, Johnson SB, TEDDY Study Group (2021) Parental monitoring for type 1 diabetes in genetically at-risk young children: the TEDDY study. Pediatr Diabetes 22(5):717–28. 10.1111/pedi.1317333704891
142. Smith LB Lynch KF Baxter J Factors associated with maternal-reported actions to prevent type 1 diabetes in the first year of the TEDDY study Diabetes Care 2014 37 2 325 31 10.2337/dc13-0449 24041684
Smith LB, Lynch KF, Baxter J et al (2014) Factors associated with maternal-reported actions to prevent type 1 diabetes in the first year of the TEDDY study. Diabetes Care 37(2):325–31. 10.2337/dc13-044924041684
143. Tluczek A Ersig AL Lee S Psychosocial issues related to newborn screening: a systematic review and synthesis Int J Neonatal Screen 2022 8 4 53 10.3390/ijns8040053 36278623
Tluczek A, Ersig AL, Lee S (2022) Psychosocial issues related to newborn screening: a systematic review and synthesis. Int J Neonatal Screen 8(4):53. 10.3390/ijns804005336278623
144. Roth R Lynch K Lernmark B Maternal anxiety about a child’s diabetes risk in the TEDDY study: the potential role of life stress, postpartum depression, and risk perception Pediatr Diabetes 2015 16 4 287 98 10.1111/pedi.12168 25082392
Roth R, Lynch K, Lernmark B et al (2015) Maternal anxiety about a child’s diabetes risk in the TEDDY study: the potential role of life stress, postpartum depression, and risk perception. Pediatr Diabetes 16(4):287–98. 10.1111/pedi.1216825082392
145. O’Donnell HK Rasmussen CG Dong F Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes Diabetes Care 2023 46 12 2155 61 10.2337/dc23-0350 37673098
O’Donnell HK, Rasmussen CG, Dong F et al (2023) Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes. Diabetes Care 46(12):2155–61. 10.2337/dc23-035037673098
146. ElSayed NA Aleppo G Aroda VR 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes—2023 Diabetes Care 2023 46 Supplement_1 S68 S96 10.2337/dc23-S005 36507648
ElSayed NA, Aleppo G, Aroda VR et al (2023) 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes—2023. Diabetes Care 46(Supplement_1):S68–S96. 10.2337/dc23-S00536507648
147. Young-Hyman D de Groot M Hill-Briggs F Gonzalez JS Hood K Peyrot M Psychosocial care for people with diabetes: a position statement of the American Diabetes Association Diabetes Care 2016 39 12 2126 40 10.2337/dc16-2053 27879358
Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M (2016) Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care 39(12):2126–40. 10.2337/dc16-205327879358
148. Wit M Gajewska KA Goethals ER ISPAD clinical practice consensus guidelines 2022: psychological care of children, adolescents and young adults with diabetes Pediatr Diabetes 2022 23 8 1373 89 10.1111/pedi.13428 36464988
Wit M, Gajewska KA, Goethals ER et al (2022) ISPAD clinical practice consensus guidelines 2022: psychological care of children, adolescents and young adults with diabetes. Pediatr Diabetes 23(8):1373–89. 10.1111/pedi.1342836464988
149. Johnson SB Smith LB General population screening for islet autoantibodies: psychosocial challenges Diabetes Care 2023 46 12 2123 5 10.2337/dci23-0061 38011529
Johnson SB, Smith LB (2023) General population screening for islet autoantibodies: psychosocial challenges. Diabetes Care 46(12):2123–5. 10.2337/dci23-006138011529
150. van Steenbergen-Weijenburg KM de Vroege L Ploeger RR Validation of the PHQ-9 as a screening instrument for depression in diabetes patients in specialized outpatient clinics BMC Health Serv Res 2010 10 235 10.1186/1472-6963-10-235 20704720
van Steenbergen-Weijenburg KM, de Vroege L, Ploeger RR et al (2010) Validation of the PHQ-9 as a screening instrument for depression in diabetes patients in specialized outpatient clinics. BMC Health Serv Res 10:235. 10.1186/1472-6963-10-23520704720
151. Hamilton M The assessment of anxiety states by rating Br J Med Psychol 1959 32 1 50 5 10.1111/j.2044-8341.1959.tb00467.x 13638508
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32(1):50–5. 10.1111/j.2044-8341.1959.tb00467.x13638508
152. Driscoll KA Melin J Lynch KF Smith LB Johnson SB SAI-CH-6: development of a short form of the state anxiety inventory for children at-risk for type 1 diabetes J Pediatr Psychol 2023 48 10 861 9 10.1093/jpepsy/jsad057 37698990
Driscoll KA, Melin J, Lynch KF, Smith LB, Johnson SB (2023) SAI-CH-6: development of a short form of the state anxiety inventory for children at-risk for type 1 diabetes. J Pediatr Psychol 48(10):861–9. 10.1093/jpepsy/jsad05737698990
153. American Diabetes Association. Diabetes Pro. Mental Health Directory. Available from: https://my.diabetes.org/health-directory. Accessed: 3 May 2024
154. Chobot A, Eckert AJ, Biester T et al (2023) Psychological care for children and adolescents with diabetes and patient outcomes: results from the international pediatric registry SWEET. Pediatr Diabetes. 10.1155/2023/8578231
155. Sims EK Besser REJ Dayan C Screening for type 1 diabetes in the general population: a status report and perspective Diabetes 2022 71 4 610 23 10.2337/dbi20-0054 35316839
Sims EK, Besser REJ, Dayan C et al (2022) Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes 71(4):610–23. 10.2337/dbi20-005435316839
156. Hummel S Ziegler AG Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies Am J Clin Nutr 2011 94 6 Suppl S1821 S1823 10.3945/ajcn.110.000646
Hummel S, Ziegler AG (2011) Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies. Am J Clin Nutr 94(6 Suppl):S1821–S1823. 10.3945/ajcn.110.000646
157. Krischer JP Lynch KF Schatz DA The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study Diabetologia 2015 58 5 980 7 10.1007/s00125-015-3514-y 25660258
Krischer JP, Lynch KF, Schatz DA et al (2015) The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58(5):980–7. 10.1007/s00125-015-3514-y25660258
158. Ilonen J Hammais A Laine AP Patterns of β-cell autoantibody appearance and genetic associations during the first years of life Diabetes 2013 62 10 3636 40 10.2337/db13-0300 23835325
Ilonen J, Hammais A, Laine AP et al (2013) Patterns of β-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 62(10):3636–40. 10.2337/db13-030023835325
159. Ziegler AG Bonifacio E BABYDIAB-BABYDIET Study Group Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes Diabetologia 2012 55 7 1937 43 10.1007/s00125-012-2472-x 22289814
Ziegler AG, Bonifacio E, BABYDIAB-BABYDIET Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55(7):1937–43. 10.1007/s00125-012-2472-x22289814
160. Lernmark Å Akolkar B Hagopian W Possible heterogeneity of initial pancreatic islet beta-cell autoimmunity heralding type 1 diabetes J Intern Med 2023 294 2 145 58 10.1111/joim.13648 37143363
Lernmark Å, Akolkar B, Hagopian W et al (2023) Possible heterogeneity of initial pancreatic islet beta-cell autoimmunity heralding type 1 diabetes. J Intern Med 294(2):145–58. 10.1111/joim.1364837143363
161. Leslie RD Evans-Molina C Freund-Brown J Adult-onset type 1 diabetes: current understanding and challenges Diabetes Care 2021 44 11 2449 56 10.2337/dc21-0770 34670785
Leslie RD, Evans-Molina C, Freund-Brown J et al (2021) Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care 44(11):2449–56. 10.2337/dc21-077034670785
162. Ziegler AG Bonifacio E Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? Diabetologia 2020 63 8 1665 6 10.1007/s00125-020-05175-8 32451571
Ziegler AG, Bonifacio E (2020) Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? Diabetologia 63(8):1665–6. 10.1007/s00125-020-05175-832451571
163. Decochez K, De Leeuw IH, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia 45(12):1658–66. 10.1007/s00125-002-0949-8
164. Achenbach P Lampasona V Landherr U Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk Diabetologia 2009 52 9 1881 8 10.1007/s00125-009-1438-0 19590848
Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 52(9):1881–8. 10.1007/s00125-009-1438-019590848
165. Bediaga NG Li-Wai-Suen CSN Haller MJ Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample Diabetologia 2021 64 11 2432 44 10.1007/s00125-021-05523-2 34338806
Bediaga NG, Li-Wai-Suen CSN, Haller MJ et al (2021) Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia 64(11):2432–44. 10.1007/s00125-021-05523-234338806
166. Simmons KM Sosenko JM Warnock M One-hour oral glucose tolerance tests for the prediction and diagnostic surveillance of type 1 diabetes J Clin Endocrinol Metab 2020 105 11 e4094 e4101 10.1210/clinem/dgaa592 32844178
Simmons KM, Sosenko JM, Warnock M et al (2020) One-hour oral glucose tolerance tests for the prediction and diagnostic surveillance of type 1 diabetes. J Clin Endocrinol Metab 105(11):e4094–e4101. 10.1210/clinem/dgaa59232844178
167. Sosenko JM Skyler JS DiMeglio LA A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history Diabetes Care 2015 38 2 271 6 10.2337/dc14-1813 25519451
Sosenko JM, Skyler JS, DiMeglio LA et al (2015) A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care 38(2):271–6. 10.2337/dc14-181325519451
168. Sosenko JM Skyler JS Mahon J Use of the Diabetes Prevention Trial-Type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes Diabetes Care 2014 37 4 979 84 10.2337/dc13-2359 24550217
Sosenko JM, Skyler JS, Mahon J et al (2014) Use of the Diabetes Prevention Trial-Type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care 37(4):979–84. 10.2337/dc13-235924550217
169. Sosenko JM Skyler JS Palmer JP Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups The development, validation, and utility of the Diabetes Prevention Trial-Type 1 risk score (DPTRS) Curr Diab Rep 2015 15 8 49 10.1007/s11892-015-0626-1 26077017
Sosenko JM, Skyler JS, Palmer JP, Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups (2015) The development, validation, and utility of the Diabetes Prevention Trial-Type 1 risk score (DPTRS). Curr Diab Rep 15(8):49. 10.1007/s11892-015-0626-126077017
170. Helminen O Pokka T Tossavainen P Ilonen J Knip M Veijola R Continuous glucose monitoring and HbA1c in the evaluation of glucose metabolism in children at high risk for type 1 diabetes mellitus Diabetes Res Clin Pract 2016 120 89 96 10.1016/j.diabres.2016.07.027 27525364
Helminen O, Pokka T, Tossavainen P, Ilonen J, Knip M, Veijola R (2016) Continuous glucose monitoring and HbA1c in the evaluation of glucose metabolism in children at high risk for type 1 diabetes mellitus. Diabetes Res Clin Pract 120:89–96. 10.1016/j.diabres.2016.07.02727525364
171. Raghinaru D Calhoun P Bergenstal RM Beck RW the optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial Diabetes Technology Ther 2022 24 12 868 72 10.1089/dia.2022.0274
Raghinaru D, Calhoun P, Bergenstal RM, Beck RW (2022) the optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial. Diabetes Technology Ther 24(12):868–72. 10.1089/dia.2022.0274
